Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists

Abstract

Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4- IBB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, in some embodiments, therapeutic combinations of TILs and TNFRSF agonists useful in the treatment of diseases such as cancer, including compositions, uses, and dosing regimens thereof, are disclosed herein.

Description

EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS ANDTHERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This international application claims the benefit of priority to U.S. Provisional Application No. 62 / 443,556, filed January 6, 2017, U.S. Provisional Application No. 62 / 460,477, filed February 17, 2017, U.S. Provisional Application No. 62 / 532,807, filed July 14, 2017, and Provisional Application No. 62 / 567,151, filed October 2, 2017, the entirety of which are incorporated herein by reference.FIELD OF THE INVENTION

[0002] Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4- IBB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, therapeutic combinations of TILs and TNFRSF agonists, including compositions and uses thereof in the treatment of diseases such as cancer are disclosed herein.BACKGROUND OF THE INVENTION

[0003] Treatment of bulky, refractory cancers using adoptive autologous transfer of tumor infiltrating lymphocytes (TILs) represents a powerful approach to therapy for patients with poor prognoses. Gattinoni, et al, Nat. Rev. Immunol. 2006, 6, 383-393. TILs are dominated by T cells, and IL-2-based TIL expansion followed by a "rapid expansion process" (REP) has become a preferred method for TIL expansion because of its speed and efficiency. Dudley, et al, Science 2002, 298, 850-54; Dudley, et al., J. Clin. Oncol. 2005, 23, 2346-57; Dudley, et al, J. Clin. Oncol. 2008, 26, 5233-39; Riddell, et al, Science 1992, 257, 238-41; Dudley, et al, J. Immunother. 2003, 26, 332-42. A number of approaches to improve clinical responses to TIL therapy in melanoma and to expand TIL therapy to other tumor types have been explored with limited success, and the field remains challenging. Goff, et al, J. Clin. Oncol. 2016, 34, 2389- 97; Dudley, et al, J. Clin. Oncol. 2008, 26, 5233-39; Rosenberg, et al., Clin. Cancer Res. 2011, 17, 4550-57. Much focus has been placed on selection of TILs during expansion to either selectparticular subsets (such as CD8+T cells) or to target driver mutations such as a mutatedERBB2IP epitope or driver mutations in the KRAS oncogene. Tran, et al , N. Engl. J. Med. 2016, 375, 2255-62; Tran, et al, Science 2014, 344, 641-45. However, such selection approaches, even if they can be developed to show efficacy in larger clinical trials, add significantly to the duration, complexity, and cost of performing TIL therapy and limit the potential for widespread use of TIL therapy in different types of cancers.

[0004] 4-lBB (also known as CD137 and TNFRSF9), which was first identified as an inducible costimulatory receptor expressed on activated T cells, is a membrane spanning glycoprotein member of the T FRSF. Watts, Annu. Rev. Immunol. 2005, 23, 23-68. 4-lBB is a type 2 transmembrane glycoprotein that is expressed on activated T lymphocytes, and to a larger extent on CD8+than CD4+T cells. 4-lBB is also expressed on dendritic cells, follicular dendritic cells, natural killer (NK) cells, granulocytes, cells of blood vessel walls at sites of inflammation, tumor vasculature, and atherosclerotic endothelium. The ligand that stimulates 4- 1BB (4-1BBL) is expressed on activated antigen-presenting cells (APCs), myeloid progenitor cells and hematopoietic stem cells. 4-lBB is an activation-induced T-cell costimulatory molecule. Signaling through 4-lBB upregulates survival genes, enhances cell division, induces cytokine production, and prevents activation-induced sell death in T cells. Currentunderstanding of 4- IBB indicates that expression is generally activation dependent and encompasses a broad subset of immune cells including activated NK and NK T cells (NKT cells); regulatory T cells; dendritic cells (DC) including follicular DCs; stimulated mast cells, differentiating myeloid cells, monocytes, neutrophils, eosinophils, and activated B cells. 4- IBB strongly enhances the proliferation and effector function of CD8+T cells. Crosslinking of 4-lBB enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Additionally, anti-4- 1BB monoclonal antibodies possess strong antitumor properties, which in turn are the result of their powerful CD8+ T-cell activating, IFN-g producing, and cytolytic marker-inducing capabilities. Vinay and Kwon, Mol. Cancer Therapeutics 2Q\2, 11, 1062-70; Lee, et al. , PLoS One, 2013, 5, e69677, 1-1 1.

[0005] Interaction of 4- IBB on activated normal human B cells with its ligand at the time of B cell receptor engagement stimulates proliferation and enhances survival. The potential impact of 4- IBB engagement in B cell lymphoma has been investigated in at least two published studies. Evaluation of several types of human primary NHL samples indicated that 4- IBB wasexpressed predominantly on infiltrating T cells rather than the lymphoma cells. Houot, et al, Blood, 2009, 114, 3431-38. The addition of 4-1BB agonists to in vitro cultures of B lymphoma cells with, rituximab and NK cells resulted in increased lymphoma killing. Kohrt, et al, Blood, 2011, 117, 2423-32. In addition, B cell immunophenotyping was performed in two experiments using PF-05082566 in cynomolgus monkeys with doses from 0.001-100 mg / kg; in these experiments peripheral blood B cell numbers were either unchanged or decreased, as described in International Patent Application Publication No. WO 2015 / 119923.

[0006] 4- IBB is undetectable on the surface of naive T cells but expression increases upon activation. Upon 4- IBB activation, two pro-survival members of the TNFR-associated factor (TRAF) family, TRAF1 and TRAF2, are recruited to the 4-1BB cytoplasmic tail, resulting in downstream activation of NFkB and the Mitogen Activated Protein (MAP) kinase cascade including Erk, Jnk, and p38 MAP kinases. NFkB activation leads to upregulation of Bfl-1 and Bel-XL, pro-survival members of the Bcl-2 family. The pro-apoptotic protein Bim is downregulated in a TRAFl and Erk dependent manner. Sabbagh, et al, J. Immunol. 2008, 180, 8093-8101. Reports have shown that 4-1BB agonist monoclonal antibodies (mAbs) increase costimulatory molecule expression and markedly enhance cytolytic T lymphocyte responses, resulting in anti-tumor efficacy in various models. 4-1BB agonist mAbs have demonstrated efficacy in prophylactic and therapeutic settings and both monotherapy and combination therapy tumor models and have established durable anti-tumor protective T cell memory responses. Lynch, et al, Immunol Rev., 2008, 222, 277-286. 4-1BB agonists also inhibit autoimmune reactions in a variety of autoimmunity models. Vinay, et al, J. Mol. Med. 2006, 84, 726-36.

[0007] The OX40 receptor (OX40) (also known as TNFRSF4, CD 134, ACT-4, and ACT35) is a member of the TNF receptor family which is expressed on activated CD4+T cells (see WO 95 / 12673). Triggering of this receptor via the OX40 ligand, named OX40L, gp34 or ACT-4- ligand, which is present on activated B-cells and dendritic cells, enhances the proliferation of CD4+T cells during an immune response and influences the formation of CD4+memory T-cells. Furthermore, the OX40-OX40L system mediates adhesion of activated T cells to endothelial cells, thus directing the activated CD4+T cells to the site of inflammation.

[0008] It has been shown that OX40+T cells are present within tumor lesions containing tumor infiltrating lymphocytes and in tumor cell positive draining lymph nodes. Weinberg, etal, J. Immunol., 2000, 164, 2160-2169. It was shown in several tumor models in mice that engagement of the OX40 receptor in vivo during tumor priming significantly delayed and prevented the appearance of tumors as compared to control treated mice. Weinberg, et al, J. Immunol, 2000, 164, 2160-2169. Hence, it has been contemplated to enhance the immune response of a mammal to an antigen by engaging the OX40-receptor by administering an OX40- receptor binding agent (International Patent Application Publication No. WO 1999 / 042585; Weinberg, et al, J. Immunol, 2000, 164, 2160-2169). Preclinical studies demonstrated that treatment of tumor bearing hosts with OX40 agonists, including both anti-OX40 monoclonal antibodies and OX40L-Fc fusion proteins, resulted in tumor regression in several preclinical models. Linch, et al , Front. Oncol. 2015, 34, 1-14.

[0009] CD27, also known as TNFRSF7, has overlapping activity with other TNFRSF members including CD40, 4-1BB, and OX40. CD27 plays a critical role in T cell survival, activation, and effector function, and also plays a role in the proliferative and cytotoxic activity of NK cells. CD27 is constitutively expressed on the majority of T cells, including naive T cells. The ligand for CD27 is CD70, which is found on T cells, B cells, and dendritic cells. Oshima, et al, Int. Immunol. 1998, 10, 517-26. CD27 drives the expansion of CD4+and CD8+T cells, acting after CD28 to sustain T effector cell survival, and influences secondary responses more than primary responses. However, CD27 activation has also been associated with tumor growth through enhancement of the immunosuppressive effects of regulatory T cells. Claus, et al, Cancer Res. 2012, 72, 3664-76. Other data has indicated that the immunostimulatory effects of CD27 may outweigh this tumor promoting effect. Aulwurm, et al, Int. J. Cancer 2006, 118, 1728-35. In mouse models, an agonistic CD27 monoclonal antibody showed antitumor efficiacy and induction of tumor immunity. He, et al, J. Immunol. 2013, 191, 4174-83.

[0010] Glucocorticoid-induced TNFR-related protein (GITR) is a costimulatory checkpoint molecule that is also known as tumor necrosis factor receptor superfamily member 18(TNFRSF 18), activation-inducible TNFR family receptor (AITR), and CD357. GITR is expressed on several cell types, including regulatory T cells (Tregs) and effector T cells, B cells, NK cells, and antigen-presenting cells. Nocentini and Riccardi, Eur. J. Immunol. 2005, 35, 1016-1022. GITR is activated by its conjugate GITR ligand (GITRL). GITR plays a role in stimulating an immune response, and antigen binding proteins to GITR have utility in treating a variety of GITR-related diseases or disorders in which it is desirable to increase an immuneresponse. Ko, et al, J. Exp. Med.2005, 202, 885-91; Shimizu, et al, Nature Immunology 2002, 3, 135-142; Cohen, et al, Cancer Res.2006, 66, 4904-12; Azuma, Crit. Rev. Immunol.2010, 30, 547-57. For example, T cell stimulation through GITR attenuates Treg-mediated suppression and enhances tumor-killing by CD4+and CD8+T cells. GITR is constitutively expressed at high levels in Tregs (such as CD4+CD25+or CD8+CD25+cells) and is additionally upregulated upon activation of these cells. Nocentini and Riccardi, Eur. J. Immunol.2005, 35, 1016-1022. GITR is a co-activating signal to both CD4+and CD8+naive T cells, and induces and enhances proliferation and effector function, particularly in situations where T cell receptor (TCR) stimulation is suboptimal. Schaer, et al, Curr. Opin. Immunol.2012, 24, 217-224. The enhanced immune response caused by antigen binding GITR proteins, such as fusion proteins and anti-GITR antibodies (including agonistic antibodies), is of interest in a variety of immunotherapy applications, such as the treatment of cancers, autoimmune diseases,inflammatory diseases, or infections.

[0011] Herpesvirus entry mediator (HVEM), also known as TNFRSF14 and CD270, was first isolated as a receptor for herpes simplex virus-1 (HSV-1). Montgomery, et al, Cell 1996, 87, 427-36. HVEM binds to the TNF family ligands LIGHT and lymphotoxin alpha homotrimer (Lta3). Mauri, et al., Immunity 1998, 8, 21-30. T cell activation can occur through the HVEM- LIGHT interaction, and the interaction provides a costimulatory signal to T cells that is independent of CD28 signaling and can be observed in the presence of suboptimal levels of CD3 antibody (OKT-3). Tamada, et al., J. Immunol.2000, 165, 4397-404; Harrop, et al., J. Biol. Chem.1998, 273, 27548-56; Tamada, et al, Nat. Med.2000, 6, 283-89; Yu, et al, Nat. Immunol. 2004, 5, 141-49. HVEM comprises four cysteine-rich domains (CRDs). del Rio, et al. , J.Leukoc. Biol.2010, 87, 223-35. CRD2 and CRD3 are required for HVEM trimerization with the TNFRSF ligand LIGHT, which delivers a co-stimulatory signal to T cells through HVEM. In contrast, CRDl and CRD2 bind to the co-inhibitory B and T lymphocyte attenuator (BTLA) receptor and CD 160 in a monomeric manner, providing an inhibitory signal to T cells. Studies of the HVEM-LIGHT interaction suggest that it primarily has a CD28-independentcostimulatory effect on CD8+ T cells, but also affects CD4+ T cells. Liu, et al, Int. Immunol. 2003, 15, 861-70; Scheu, et al, J. Exp. Med.2002, 195, 1613-24.

[0012] CD95, also known as Fas, APO-1, and TNFRSF6, is a 45 kDa type-I transmembrane protein which, unlike 4-1BB, OX40, GITR, CD27, and HVEM, contains a death domain.Kischkel, et al, EMBO J. 1995, 14, 5579-88; Krammer, Nature 2000, 407, 789-95. The binding of the inducible CD95 ligand (CD95L) to CD95 on activated T cells leads to apoptotic cell death, and thus it is not normally associated with the same costimulatory function as 4- IBB, OX40, GITR, CD27, and HVEM. Strauss, et al, J. Exp. Med. 2009, 206, 1379-93. However, CD95 also behaves as a dual function receptor that provides for anti-apoptotic and costimulatory effects on T cells under some conditions. Paulsen, et al., Cell Death Differ. 2011, 18, 619-31. CD95 engagement modulates TCR-driven signal initiation in a dose-dependent manner, wherein high doses of CD95 agonists or cellular CD95L silence T cells, while lower doses of these agonists strongly enhance TCR-driven T cell activation and proliferation.

[0013] The present invention provides the unexpected finding that T FRSF agonists, such as a 4- IBB agonist, a CD27 agonist, a GITR agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, are useful in the expansion of TILs from tumors from which it is known to be difficult to obtain TILs and treat the tumor with TILs, and are further useful in the treatment of patients in combination with TIL therapy.SUMMARY OF THE INVENTION

[0014] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSFagonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer.

[0015] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is selected from the group consisting of a 4- IBB agonist, an OX40 agonist, a CD27 agonist, a GITR agonist, a HVEM agonist, a CD95 agonist, and combinations thereof.

[0016] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a 4-1BB agonist, and the 4-1BB agonist is selected from the group consisting of urelumab, utomilumab, EU-101 and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0017] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a 4-1BB agonist, and the 4-1BB agonist is a 4- IBB agonist fusion protein.

[0018] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a 4- IBB agonist fusion protein, and the 4-1BB agonist fusion protein comprises (i) a first soluble 4-1BB binding domain, (ii) a first peptide linker, (iii) a second soluble 4- IBB binding domain, (iv) a second peptide linker, and (v) a third soluble 4- IBB binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structureaccording to structure I- A or structure I-B.

[0019] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a OX40 agonist, and the OX40 agonist is selected from the group consisting of tavolixizumab, GSK3174998, MEDI6469, MEDI6383, MOXR0916, PF-04518600, Creative Biolabs MOM-18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0020] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is atleast 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is an OX40 agonist, and the OX40 agonist is an OX40 agonist fusion protein.

[0021] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is an OX40 agonist fusion protein, and the OX40 agonist fusion protein comprises (i) a first soluble OX40 binding domain, (ii) a first peptide linker, (iii) a second soluble OX40 binding domain, (iv) a second peptide linker, and (v) a third soluble OX40 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I- A or structure I-B.

[0022] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a CD27 agonist, and the CD27 agonist is varlilumab, or a fragment, derivative, variant, or biosimilar thereof.

[0023] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a CD27 agonist, and wherein the CD27 agonist is an CD27 agonist fusion protein.

[0024] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a CD27 agonist, and the CD27 agonist fusion protein comprises (i) a first soluble CD27 binding domain, (ii) a first peptide linker, (iii) a second soluble CD27 binding domain, (iv) a second peptide linker, and (v) a third soluble CD27 binding domain, further comprising an additional domain at the N- terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I- A or structure I-B.

[0025] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a GITR agonist, and the GITR agonist is selected from the group consisting of TRX518, 6C8, 36E5, 3D6, 61G6, 6H6, 61F6, 1D8, 17F10, 35D8, 49A1, 9E5, 31H6, 2155, 698, 706, 827, 1649, 1718, 1D7, 33C9, 33F6, 34G4, 35B10, 41E11, 41G5, 42A11, 44C1, 45A8, 46E11, 48H12, 48H7, 49D9, 49E2, 48A9, 5H7, 7A10, 9H6, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0026] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is an GITR agonist, and the GITR agonist is a GITR agonist fusion protein.

[0027] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a GITR agonist fusion protein, and the GITR agonist fusion protein comprises (i) a first soluble GITR binding domain, (ii) a first peptide linker, (iii) a second soluble GITR binding domain, (iv) a second peptide linker, and (v) a third soluble GITR binding domain, further comprising an additional domain at the N- terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I- A or structure I-B.

[0028] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist,and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a HVEM agonist.

[0029] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is an HVEM agonist, and the HVEMagonist is a HVEM agonist fusion protein.

[0030] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is a HVEM agonist fusion protein, and wherein the HVEM agonist fusion protein comprises (i) a first soluble HVEM binding domain, (ii) a first peptide linker, (iii) a second soluble HVEM binding domain, (iv) a second peptide linker, and (v) a third soluble HVEM binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I- A or structure I-B.

[0031] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with the TNFRSF agonist starting on the day after administration of the third population of TILs to the patient, wherein the TNFRSF agonist is administered intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

[0032] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with the TNFRSF agonist prior to the step of resecting of a tumor from the patient, wherein the TNFRSF agonist is administered intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

[0033] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is selected from the group consisting of urelumab, utomilumab, EU-101, tavolixizumab, Creative Biolabs MOM-18455, andfragments, derivatives, variants, biosimilars, and combinations thereof.

[0034] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the first cell culture medium comprises a second TNFRSF agonist.

[0035] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist,and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is added to the first cell culture medium during the initial expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

[0036] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is added to the second cell culture medium during the rapid expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

[0037] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 0.1 μg / mL and 100 μg / mL.

[0038] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 μg / mL and 40 μg / mL.

[0039] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSFagonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 10 to about 6000 IU / mL in the first cell culture medium.

[0040] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 3000 IU / mL in the first cell culture medium.

[0041] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, The method of Claim 31, wherein IL-2 is present at an initial concentration of about 800 to about 1100 R7 / mL in the first cell culture medium.

[0042] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSFagonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 1000 IU / mL in the first cell culture medium.

[0043] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 10 to about 6000 IU / mL in the second cell culture medium.

[0044] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 3000 IU / mL in the second cell culture medium.

[0045] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSFagonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 800 to about 1100 IU / mL in the second cell culture medium.

[0046] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-2 is present at an initial concentration of about 1000 IU / mL in the second cell culture medium.

[0047] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-15 is present in the first cell culture medium.

[0048] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

[0049] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-15 is present in the second cell culture medium.

[0050] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is atleast 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

[0051] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-21 is present in the first cell culture medium.

[0052] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

[0053] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culturemedium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein IL-21 is present in the second cell culture medium.

[0054] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to apatient with the cancer, wherein IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

[0055] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein OKT-3 antibody is present at an initial concentration of about 10 ng / mL to about 60 ng / mL in the second cell culture medium.

[0056] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culturemedium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein OKT-3 antibody is present at an initial concentration of about 30 ng / mL in the second cell culture medium.

[0057] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the initial expansion is performed using a gas permeable container.

[0058] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the rapid expansion is performed using a gas permeable container.

[0059] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is atleast 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a non- myeloablative lymphodepletion regimen prior to administering the third population of TILs to the patient.

[0060] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a non- myeloablative lymphodepletion regimen prior to administering the third population of TILs to the patient, wherein the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg / m2 / day for two days followed by administration of fludarabine at a dose of 25 mg / m2 / day for five days.

[0061] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a decrescendo IL-2 regimen starting on the day after administration of the third population of TILs to the patient, wherein the decrescendo IL-2 regimen comprises aldesleukin administered intravenously at a dose of 18,000,000 IU / m2on day 1, 9,000,000 IU / m2on day 2, and 4,500,000 IU / m2on days 3 and 4.

[0062] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with pegylated IL-2 after administration of the third population of TILs to the patient at a dose of 0.10 mg / day to 50 mg / day.

[0063] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist,and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs to the patient.

[0064] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs to the patient, wherein the high-dose IL-2 regimen comprises 600,000 or 720,000 IU / kg of aldesleukin, or a biosimilar or variant thereof, administered as a 15-minute bolus intravenous infusion every eight hours until tolerance.

[0065] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, renal cell carcinoma, acute myeloid leukemia, colorectal cancer, cholangiocarcinoma, and sarcoma.

[0066] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, wherein the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), triple negative breast cancer, double-refractory melanoma, and uveal (ocular) melanoma.

[0067] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culturemedium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a PD-1 inhibitor or PD-L1 inhibitor prior to resecting the tumor from the patient.

[0068] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a PD-1 inhibitor or PD-L1 inhibitor prior to resecting the tumor from the patient, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab,pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0069] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a PD-1 inhibitor or PD-L1 inhibitor after resecting the tumor from the patient.

[0070] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culturemedium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a PD-1 inhibitor or PD-L1 inhibitor after resecting the tumor from the patient, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab,pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0071] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSFagonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a PD-1 inhibitor or PD-L1 inhibitor after administering the third population of TILs to the patient.

[0072] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to a patient with the cancer, further comprising the step of treating the patient with a PD-1 inhibitor or PD-L1 inhibitor after administering the third population of TILs to the patient, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0073] In an embodiment, the invention provides a process for the preparation of a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(b) obtaining a first population of TILs;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less; and(e) harvesting the third population of TILs.

[0074] In an embodiment, the invention provides a population of tumor infiltrating lymphocytes (TILs) obtainable from a process comprising the steps of:(b) obtaining a first population of TILs;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less; and(e) harvesting the third population of TILs.

[0075] In an embodiment, the invention provides a population of TILs is for use in the treatement of cancer. In an embodiment, the invention provides a pharmaceutical composition comprising a population of tumor infiltrating lymphocytes (TILs) for use in treating a cancer wherein the population of tumor infiltrating lymphocytes (TILs) is obtainable by a process comprising the steps of:(b) obtaining a first population of TILs;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less; and(e) harvesting the third population of TILs.

[0076] In an embodiment, the first population of TILs is obtained from a tumor. In an embodiment, the tumor is firstly resected from a patient. In an embodiment, the first population of TILs is obtained from the tumor which has been resected from a patient. In an embodiment, the population of TILs is for adminsitration in a therapeutically effective amount to a patient with cancer.

[0077] In an embodiment, the invention provides a method of expanding a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2, and wherein the initial expansion is performed over a period of 11 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3) antibody, peripheral blood mononuclear cells (PBMCs), and a TNFRSF agonist, and wherein the rapid expansion is performed over a period of 11 days or less;(e) harvesting the third population of TILs; and(f) optionally cryopreserving the third population of TILs in a dimethylsulfoxide-based media.

[0078] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2, and wherein the initial expansion is performed over a period of 11 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3) antibody, peripheral blood mononuclear cells (PBMCs), and aTNFRSF agonist, and wherein the rapid expansion is performed over a period of 11 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to the patient.

[0079] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2, and wherein the initial expansion is performed over a period of 11 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3) antibody, peripheral blood mononuclear cells (PBMCs), and a TNFRSF agonist, and wherein the rapid expansion is performed over a period of 11 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to the patient, wherein the TNFRSF agonist is selected from the group consisting of a 4- IBB agonist, an OX40 agonist, and a combination thereof.

[0080] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2, and wherein the initial expansion is performed over a period of 11 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3) antibody, peripheral blood mononuclear cells (PBMCs), and a TNFRSF agonist, and wherein the rapid expansion is performed over a period of 11 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to the patient, wherein the TNFRSF agonist is selected from the group consisting of a 4- IBB agonist, an OX40 agonist, and a combination thereof, and wherein the TNFRSF agonist is a 4- IBB agonist, and the 4- IBB agonist is selected from the group consisting of urelumab, utomilumab, EU-101, a fusion protein, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0081] In an embodiment, the invention provides a method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILsis at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2, and wherein the initial expansion is performed over a period of 11 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3) antibody, peripheral blood mononuclear cells (PBMCs), and a TNFRSF agonist, and wherein the rapid expansion is performed over a period of 11 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to the patient, wherein the TNFRSF agonist is selected from the group consisting of a 4- IBB agonist, an OX40 agonist, and a combination thereof, and wherein the TNFRSF agonist is a OX40 agonist, and the OX40 agonist is selected from the group consisting of tavolixizumab, GSK3174998, MEDI6469, MEDI6383, MOXR0916, PF-04518600, Creative Biolabs MOM- 18455, and fragments, derivatives, variants, biosimilars, and combinations thereof. wherein the 0X4 agonist is present at the start of step (d) at a concentration between 1 μg / mL and 30 μg / mL.

[0082] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the TNFRSF agonist is present at the start of step (d) at a concentration between 5 μg / mL and 20 μg / mL.

[0083] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the TNFRSF agonist is present at the start of step (d) at a concentration of about 10 μg / mL.

[0084] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the TNFRSF agonist is maintained throughout step (d) at a concentrationbetween 1 μg / mL and 30 μg / mL.

[0085] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the TNFRSF agonist is maintained throughout step (d) at a concentration between 5 μg / mL and 20 μg / mL.

[0086] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the TNFRSF agonist is maintained throughout step (d) at a concentration of about 10 μg / mL.

[0087] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the third population of TILs exhibits an increased ratio of CD8+TILs to CD4+TILs in comparison to the reference ratio of CD8+TILs to CD4+TILs in the second population of TILs. In an embodiment, the increased ratio is selected from the group consisting of at least 1% greater than the reference ratio, at least 2% greater than the reference ratio, at least 5% greater than the reference ratio, at least 10% greater than the reference ratio, at least 15% greater than the reference ratio, at least 20% greater than the reference ratio, at least 25% greater than the reference ratio, at least 30% greater than the reference ratio, at least 35% greater than the reference ratio, at least 40% greater than the reference ratio, at least 45% greater than the reference ratio, and at least 50% greater than the reference ratio. In an embodiment, the increased ratio is between 5% and 80% greater than the reference ratio. In an embodiment, the increased ratio is between 10% and 70% greater than the reference ratio. In an embodiment, the increased ratio is between 15% and 60% greater than the reference ratio. In an of the foregoing embodiments, the reference ratio is obtained from a third TIL population that is a responder to the TNFRSF agonist.

[0088] In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the cancer is selected from the group consisting of melanoma, uveal (ocular) melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer (head and neck squamous cell cancer), renal cell carcinoma, colorectal cancer, pancreatic cancer, glioblastoma, cholangiocarcinoma, and sarcoma. In an embodiment, the invention provides a method of any of the foregoing embodiments, wherein the cancer is selected from the group consisting of cutaneous melanoma, uveal (ocular) melanoma, platinum- resistant ovarian cancer, pancreatic ductal adenocarcinoma, osteosarcoma, triple-negative breastcancer, and non-small-cell lung cancer.

[0089] In an embodiment, any of the foregoing embodiments may be combined with any of the following embodiments.

[0090] In an embodiment, the process is an in vitro or an ex vivo process.

[0091] In an embodiment, the T FRSF agonist is selected from the group consisting of a 4- 1BB agonist, an OX40 agonist, a CD27 agonist, a GITR agonist, a HVEM agonist, a CD95 agonist, and combinations thereof.

[0092] In an embodiment, the TNFRSF agonist is a 4- IBB agonist.

[0093] In an embodiment, the TNFRSF agonist is a 4-1BB agonist, and the 4-1BB agonist is selected from the group consisting of urelumab, utomilumab, EU-101 and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0094] In an embodiment, the TNFRSF agonist is a 4-1BB agonist, and the 4-1BB agonist is a 4-1BB agonist fusion protein.

[0095] In an embodiment, the TNFRSF agonist is a 4-1BB agonist fusion protein, and the 4- 1BB agonist fusion protein comprises (i) a first soluble 4- IBB binding domain, (ii) a first peptide linker, (iii) a second soluble 4- IBB binding domain, (iv) a second peptide linker, and (v) a third soluble 4- IBB binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

[0096] In an embodiment, the TNFRSF agonist is a OX40 agonist.

[0097] In an embodiment, the TNFRSF agonist is a OX40 agonist, and the OX40 agonist is selected from the group consisting of tavolixizumab, GSK3174998, MEDI6469, MEDI6383, MOXR0916, PF-04518600, Creative Biolabs MOM-18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0098] In an embodiment, the TNFRSF agonist is an OX40 agonist, and the OX40 agonist is an OX40 agonist fusion protein.

[0099] In an embodiment, the T FRSF agonist is an OX40 agonist fusion protein, and the OX40 agonist fusion protein comprises (i) a first soluble OX40 binding domain, (ii) a first peptide linker, (iii) a second soluble OX40 binding domain, (iv) a second peptide linker, and (v) a third soluble OX40 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

[0100] In an embodiment, the TNFRSF agonist is a CD27 agonist.

[0101] In an embodiment, the TNFRSF agonist is a CD27 agonist, and the CD27 agonist is varlilumab, or a fragment, derivative, variant, or biosimilar thereof.

[0102] In an embodiment, the TNFRSF agonist is a CD27 agonist, and wherein the CD27 agonist is an CD27 agonist fusion protein.

[0103] In an embodiment, the TNFRSF agonist is a CD27 agonist, and the CD27 agonist fusion protein comprises (i) a first soluble CD27 binding domain, (ii) a first peptide linker, (iii) a second soluble CD27 binding domain, (iv) a second peptide linker, and (v) a third soluble CD27 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

[0104] In an embodiment, the TNFRSF agonist is a GITR agonist.

[0105] In an embodiment, the TNFRSF agonist is a GITR agonist, and the GITR agonist is selected from the group consisting of TRX518, 6C8, 36E5, 3D6, 61G6, 6H6, 61F6, 1D8, 17F10, 35D8, 49A1, 9E5, 31H6, 2155, 698, 706, 827, 1649, 1718, 1D7, 33C9, 33F6, 34G4, 35B 10, 41E11, 41G5, 42A11, 44C1, 45A8, 46E11, 48H12, 48H7, 49D9, 49E2, 48A9, 5H7, 7A10, 9H6, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0106] In an embodiment, the TNFRSF agonist is an GITR agonist, and the GITR agonist is a GITR agonist fusion protein.

[0107] In an embodiment, the TNFRSF agonist is a GITR agonist fusion protein, and the GITR agonist fusion protein comprises (i) a first soluble GITR binding domain, (ii) a first peptide linker, (iii) a second soluble GITR binding domain, (iv) a second peptide linker, and (v)a third soluble GITR binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

[0108] In an embodiment, the TNFRSF agonist is a HVEM agonist.

[0109] In an embodiment, the TNFRSF agonist is an HVEM agonist, and the HVEM agonist is a HVEM agonist fusion protein.

[0110] In an embodiment, the TNFRSF agonist is a HVEM agonist fusion protein, and wherein the HVEM agonist fusion protein comprises (i) a first soluble HVEM binding domain, (ii) a first peptide linker, (iii) a second soluble HVEM binding domain, (iv) a second peptide linker, and (v) a third soluble HVEM binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

[0111] In an embodiment, the TNFRSF agonist is selected from the group consisting of urelumab, utomilumab, EU-101, tavolixizumab, Creative Biolabs MOM-18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0112] In an embodiment, the first cell culture medium comprises a second TNFRSF agonist.

[0113] In an embodiment, the TNFRSF agonist is added to the first cell culture medium during the initial expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

[0114] In an embodiment, the TNFRSF agonist is added to the second cell culture medium during the rapid expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

[0115] In an embodiment, the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 0.1 μg / mL and 100 μg / mL.

[0116] In an embodiment, the T FRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 μ§ / πιΙ. and 40 μ§ / πιΙ..

[0117] Further details of the TNFRSF agonists are provided herein.

[0118] In an embodiment, JL-2 is present at an initial concentration of about 10 to about 6000 R7 / mL in the first cell culture medium.

[0119] In an embodiment, JL-2 is present at an initial concentration of about 3000 IU / mL the first cell culture medium.

[0120] In an embodiment, JL-2 is present at an initial concentration of about 800 to about 1100 R7 / mL in the first cell culture medium.

[0121] In an embodiment, JL-2 is present at an initial concentration of about 1000 IU / mL the first cell culture medium.

[0122] In an embodiment, JL-2 is present at an initial concentration of about 10 to about 6000 R7 / mL in the second cell culture medium.

[0123] In an embodiment, JL-2 is present at an initial concentration of about 3000 IU / mL the second cell culture medium.

[0124] In an embodiment, IL-2 is present at an initial concentration of about 800 to about 1100 R7 / mL in the second cell culture medium.

[0125] In an embodiment, IL-2 is present at an initial concentration of about 1000 IU / mL the second cell culture medium.

[0126] In an embodiment, IL-15 is present in the first cell culture medium.

[0127] In an embodiment, IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

[0128] In an embodiment, IL-15 is present in the second cell culture medium.

[0129] In an embodiment, IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

[0130] In an embodiment, IL-21 is present in the first cell culture medium.

[0131] In an embodiment, IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

[0132] In an embodiment, IL-21 is present in the second cell culture medium.

[0133] In an embodiment, IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

[0134] In an embodiment, OKT-3 antibody is present at an initial concentration of about 10 ng / mL to about 60 ng / mL in the second cell culture medium.

[0135] In an embodiment, OKT-3 antibody is present at an initial concentration of about 30 ng / mL in the second cell culture medium.

[0136] In an embodiment, the initial expansion is performed using a gas permeable container.

[0137] In an embodiment, the rapid expansion is performed using a gas permeable container.

[0138] In an embodiment, the invention provides a population of tumor infiltrating lymphocytes (TILs) for use in treating a cancer wherein the population of tumor infiltrating lymphocytes (TILs) is obtainable by a process of the invention as described herein.

[0139] In an embodiment, the invention provides a pharmaceutical composition comprising a population of tumor infiltrating lymphocytes (TILs) for use in a method of treating a cancer wherein the population of tumor infiltrating lymphocytes (TILs) is obtainable by a process of the invention as described herein.

[0140] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a TNFRSF.

[0141] In an embodiment, the invention provides a combination of a population of TILs obtainable by a process of the invention as described herein and a TNFRSF for use in the treatment of cancer.

[0142] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a TNFRSF agonist wherein the TNFRSF agonist is for administration on the day after administration of the third population of TILs to the patient,and wherein the TNFRSF agonist is administered intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

[0143] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a TNFRSF agonist wherein the TNFRSF agonist is for administration prior to the step of resecting of a tumor from the patient, and wherein the TNFRSF agonist for administration intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

[0144] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a non-myeloablative lymphodepletion regimen.

[0145] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a non-myeloablative lymphodepletion regimen prior to administering the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient.

[0146] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a non-myeloablative lymphodepletion regimen prior to administering the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient, wherein the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg / m2 / day for two days followed by administration of fludarabine at a dose of 25 mg / m2 / day for five days. Further details of the non-myeloablative lymphodepletion regimen are provided herein, e.g., under the Heading "Non-Myeloablative Lymphodepletion withChemotherapy".

[0147] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a IL-2 regimen.

[0148] In an embodiment, the IL-2 regimen is a decrescendo IL-2 regimen.

[0149] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a decrescendo IL-2 regimen starting on the day after administration of the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient, wherein the decrescendo IL-2 regimencomprises aldesleukin administered intravenously at a dose of 18,000,000 IU / m2on day 1, 9,000,000 IU / m2on day 2, and 4,500,000 IU / m2on days 3 and 4.

[0150] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with pegylated IL-2.

[0151] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in a method of treating cancer in combination with pegylated IL-2 administered after administration of the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient at a dose of 0.10 mg / day to 50 mg / day.

[0152] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in a method of treating cancer in combination with a high-dose IL-2 regimen.

[0153] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in a method of treating cancer in combination with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient.

[0154] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient, wherein the high-dose IL-2 regimen comprises 600,000 or 720,000 IU / kg of aldesleukin, or a biosimilar or variant thereof, administered as a 15- minute bolus intravenous infusion every eight hours until tolerance.

[0155] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer, wherein the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, renal cell carcinoma, acute myeloid leukemia, colorectal cancer, cholangiocarcinoma, and sarcoma.

[0156] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer, wherein the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), triple negative breast cancer, double-refractory melanoma, and uveal (ocular) melanoma.

[0157] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor.

[0158] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0159] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor, wherein the PD-1 inhibitor or PD-Ll inhibitor is for administration prior to resecting the tumor from the patient.

[0160] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor prior to resecting the tumor from the patient, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0161] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in method of treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor.

[0162] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0163] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in a method of treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor after resecting the tumor from the patient.

[0164] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor after resecting the tumor from the patient, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from thegroup consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

[0165] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor, wherein the PD-1 or PD-Ll inhibitor is for administration after administering the third population of TILs and / or a pharmaceutical composition comprising the third population of TILs to the patient.

[0166] In an embodiment, the population of TILs and / or the pharmaceutical composition is for use in treating cancer in combination with a PD-1 inhibitor or PD-Ll inhibitor which is for administrationafter administering the third population of TILs to the patient, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof. Further details of the PD-1 inhibitor and the PD-Ll inhibitor are described herein e.g. under the heading "Combinations with PD-1 and PD-Ll Inhibitors". In some embodiments, the population of TILs and / or the pharmaceutical composition comprising a population of TILs further comprise one or more features as described herein, for example, under the headings "Pharmaceutical Compositions, Dosages, and Dosing Regimens for TILs" and "Pharmaceutical Compositions, Dosages, and Dosing Regimens for T FRSF Agonists".BRIEF DESCRIPTION OF THE DRAWINGS

[0167] The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings.

[0168] FIG. 1 illustrates a TIL expansion and treatment process. TNFRSF agonists of the present disclosure may be used in both the pre-REP stage (top half of figure) or REP stage (bottom half of figure) and may be added when IL-2 is added to each cell culture. Step 1 refers to the addition of 4 tumor fragments into 10 G-Rex 10 flasks. At step 2, approximately 40 x 106TILs or greater are obtained. At step 3, a split occurs into 36 G-Rex 100 flasks for REP. TILs are harvested by centrifugation at step 4. Fresh TIL product is obtained at step 5 after a total process time of approximate 43 days, at which point TILs may be infused into a patient.

[0169] FIG. 2 illustrates a treatment protocol for use with TILs expanded with TNFRSF agonists of the present disclosure. Surgery (and tumor resection) occurs at the start, andlymphodepletion chemo refers to non-myeloablative lymphodepletion with chemotherapy as described elsewhere herein. TNFRSF agonists of the present disclosure may also be used during therapy as described herein after administration of TILs.

[0170] FIG. 3 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 4B5 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a green fluorescent protein (GFP) reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0171] FIG. 4 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 1C4 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0172] FIG. 5 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 9B4 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0173] FIG. 6 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 1D7 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0174] FIG. 7 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 1D10 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0175] FIG. 8 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 3C2 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0176] FIG. 9 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 10D12 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0177] FIG. 10 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 8D2 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0178] FIG. 11 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 4G6 activates 4- IBB signaling on Jurkat cells expressing F-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0179] FIG. 12 illustrates the results of an assay to determine if 4-lBB-Fc hybridoma 8E3 activates 4- IBB signaling on Jurkat cells expressing NF-kB using a GFP reporter in a dose dependent manner. "Secondary" refers to activation of a secondary antibody.

[0180] FIG. 13 illustrates an exemplary TIL expansion and manufacturing protocol (Process 2A).

[0181] FIG. 14 illustrates exemplary method steps undertaken in Process 2A.

[0182] FIG. 15 illustrates an exemplary TIL expansion protocol.

[0183] FIG. 16 illustrates binding affinity for Creative Biolabs (CB) and BPS Biosciences (BPS) 4-lBB agonist antibodies as assessed by percentage of 4-1BB+ cells by flow cytometry. CB 4- IBB agonist exhibited the highest binding affinity.

[0184] FIG. 17 illustrates binding affinity for Creative Biolabs (CB) and BPS Biosciences (BPS) 4-lBB agonist antibodies as assessed by mean fluorescence intensity (MFI). CB 4-lBB agonist exhibited the highest binding affinity.

[0185] FIG. 18 illustrates the results of an assessment of NF-κΒ pathway activation of anti-4- 1BB agonistic antibodies.

[0186] FIG. 19 illustrates binding affinity for Creative Biolabs OX40 agonist antibody as assessed by percentage of OX40+cells by flow cytometry.

[0187] FIG. 20 illustrates binding affinity for Creative Biolabs OX40 agonist antibodies as assessed by mean fluorescence intensity (MFI).

[0188] FIG. 21 illustrates comparable binding affinity between Creative Biolabs anti-OX40 agonist antibody (at five concentrations shown) and a commercial anti-OX40 (clone Ber- ACT35) agonist. The first letter of each tumor designation indicates histology: C = cervical; H = head and neck (head and neck squamous cell carcinoma); L = lung; and M = melanoma.

[0189] FIG. 22 illustrates the results of an assessment of NF-κΒ pathway activation of anti- OX40 agonist antibody. OX40 reporter cells were treated with either anti-OX40 alone or Isotypecontrol at the concentrations of 1, 2, 4, 8, and 16 μ§ / ιηΙ. with or without PBMC feeder cells for 24 hours. The cells were lysed using One-Step Luciferase reagent, and luciferase activity was measured by luminometer.

[0190] FIG. 23 illustrates the experimental design for 4-lBB and OX40 agonist experiments during pre-REP.

[0191] FIG. 24 illustrates the tumor histologies used in the experimental design of FIG. 23.

[0192] FIG. 25 illustrates the data analysis strategy used to assess the impact of 4- IBB and anti-OX40 agonists used during pre-REP on TIL performance and properties.

[0193] FIG. 26 illustrates total cell count results for cell expansion using CB 4-lBB agonist (N = 3). NT = not tested (control). The p value was > 0.99.

[0194] FIG. 27 illustrates total cell count results for cell expansion using CB OX40 agonist (N = 5). NT = not tested (control). The p value was 0.06.

[0195] FIG. 28 illustrates total cell count results for cell expansion using CB 4-lBB agonist and OX-40 agonist (N = 2). NT = not tested (control).

[0196] FIG. 29 illustrates total CD8+cell count results for cell expansion using CB 4- IBB agonist (N = 3). The p value was 0.5.

[0197] FIG. 30 illustrates total CD8+cell count results for cell expansion using CB OX40 agonist (N = 5). The p value was 0.03.

[0198] FIG. 31 illustrates total CD8+cell count results for cell expansion using CB 4- IBB agonist and OX-40 agonist (N = 2). NT = not tested (control).

[0199] FIG. 32 illustrates total CD8+ / CD4+cell count ratio results for cell expansion using CB 4- IBB agonist (N = 3). The p value was 0.2.

[0200] FIG. 33 illustrates total CD8+ / CD4+cell count ratio results for cell expansion using CB OX40 agonist (N = 5). The p value was 0.12.

[0201] FIG. 34 illustrates total CD8+ / CD4+cell count ratio results for cell expansion using CB 4- IBB agonist and OX-40 agonist (N = 2). NT = not tested (control).

[0202] FIG. 35 illustrates the experimental scheme for REP propagation of pre-REP TILs expanded in the presence of 4-1BB or OX40 agonists.

[0203] FIG. 36 illustrates fold expansion of TILs expanded in REP from pre-REP TILs expaned in the presence of CB 4- IBB agonist versus TILs not treated in the pre-REP (NT).

[0204] FIG. 37 illustrates fold expansion of TILs expanded in REP from pre-REP TILs expaned in the presence of CB OX40 agonist versus TILs not treated in the pre-REP (NT).

[0205] FIG. 38 illustrates fold expansion of TILs expanded in REP from pre-REP TILs expaned in the presence of CB 4- IBB agonist and CB OX40 agonist versus TILs not treated in the pre-REP (NT).

[0206] FIG. 39 illustrates the histologies of twenty-one TIL lines used for assessment of CB OX40 agonist during the REP phase.

[0207] FIG. 40 illustrates the experimental scheme for assessment of CB OX40 agonist during the REP phase.

[0208] FIG. 41 illustrates that the presence of an OX40 agonistic antibody preferentially expands CD8+TIL during REP (shown as a percentage of CD3+CD4+cells).

[0209] FIG. 42 illustrates that the presence of an OX40 agonistic antibody preferentially expands CD8+TIL during REP (shown as a percentage of CD3+CD8+cells).

[0210] FIG. 43 illustrates that in non-responder TIL lines, down-regulation of OX40 was not observed in CD4+subset following anti-OX40 treatment.

[0211] FIG. 44 illustrates experimental details for CB OX40 agonist dose titration in non- responder and responder TIL lines.

[0212] FIG. 45 illustrates the results of CB OX40 agonist dose titration in responder TIL lines.

[0213] FIG. 46 illustrates the results of CB OX40 agonist dose titration in non-responder TIL lines.

[0214] FIG. 47 illustrates comparable TCRvb repertoire profiles for responder L4005.

[0215] FIG. 48 illustrates comparable TCRvb repertoire profiles for responder H3005.

[0216] FIG. 49 illustrates comparable TCRvb repertoire profiles for responder Ml 022.BRIEF DESCRIPTION OF THE SEQUENCE LISTING

[0217] SEQ ID NO : 1 is the amino acid sequence of the heavy chain of muromonab.

[0218] SEQ ID NO 2 is the amino acid sequence of the light chain of muromonab.

[0219] SEQ ID NO 3 is the amino acid sequence of a recombinant human IL-2 protein.

[0220] SEQ ID NO: 4 is the amino acid sequence of aldesleukin.

[0221] SEQ ID NO 5 is the amino acid sequence of a recombinant human IL-4 protein.

[0222] SEQ ID NO 6 is the amino acid sequence of a recombinant human IL-7 protein.

[0223] SEQ ID NO 7 is the amino acid sequence of a recombinant human IL-15 protein

[0224] SEQ ID NO 8 is the amino acid sequence of a recombinant human IL-21 protein

[0225] SEQ ID NO: 9 is the amino acid sequence of human 4-lBB.

[0226] SEQ ID NO: 10 is the amino acid sequence of murine 4-lBB.

[0227] SEQ ID NO: 11 is the heavy chain for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0228] SEQ ID NO: 12 is the light chain for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0229] SEQ ID NO: 13 is the heavy chain variable region (VH) for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0230] SEQ ID NO: 14 is the light chain variable region (VL) for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0231] SEQ ID NO: 15 is the heavy chain CDRl for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0232] SEQ ID NO: 16 is the heavy chain CDR2 for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0233] SEQ ID NO: 17 is the heavy chain CDR3 for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0234] SEQ ID NO: 18 is the light chain CDRl for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0235] SEQ ID NO: 19 is the light chain CDR2 for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0236] SEQ ID NO:20 is the light chain CDR3 for the 4-lBB agonist monoclonal antibody utomilumab (PF-05082566).

[0237] SEQ ID NO:21 is the heavy chain for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0238] SEQ ID NO:22 is the light chain for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0239] SEQ ID NO:23 is the heavy chain variable region (VH) for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0240] SEQ ID NO:24 is the light chain variable region (VL) for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0241] SEQ ID NO:25 is the heavy chain CDRl for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0242] SEQ ID NO:26 is the heavy chain CDR2 for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0243] SEQ ID NO:27 is the heavy chain CDR3 for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0244] SEQ ID NO:28 is the light chain CDRl for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0245] SEQ ID NO:29 is the light chain CDR2 for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0246] SEQ ID NO:30 is the light chain CDR3 for the 4-lBB agonist monoclonal antibody urelumab (BMS-663513).

[0247] SEQ ID NO:31 is an Fc domain for a TNFRSF agonist fusion protein.

[0248] SEQ ID NO:32 is a linker for a T FRSF agonist fusion protein.

[0249] SEQ ID NO:33 is a linker for a TNFRSF agonist fusion protein.

[0250] SEQ ID NO:34 is a linker for a TNFRSF agonist fusion protein.

[0251] SEQ ID NO:35 is a linker for a TNFRSF agonist fusion protein.

[0252] SEQ ID NO:36 is a linker for a TNFRSF agonist fusion protein.

[0253] SEQ ID NO:37 is a linker for a TNFRSF agonist fusion protein.

[0254] SEQ ID N0.38 is a linker for a TNFRSF agonist fusion protein.

[0255] SEQ ID NO:39 is a linker for a TNFRSF agonist fusion protein.

[0256] SEQ ID NO:40 is a linker for a TNFRSF agonist fusion protein.

[0257] SEQ ID NO:41 is a linker for a TNFRSF agonist fusion protein.

[0258] SEQ ID NO:42 is an Fc domain for a TNFRSF agonist fusion protein.

[0259] SEQ ID NO:43 is a linker for a TNFRSF agonist fusion protein.

[0260] SEQ ID NO:44 is a linker for a TNFRSF agonist fusion protein.

[0261] SEQ ID NO:45 is a linker for a TNFRSF agonist fusion protein.

[0262] SEQ ID NO:46 is a 4-lBB ligand (4-1BBL) amino acid sequence.

[0263] SEQ ID NO:47 is a soluble portion of 4-1BBL polypeptide.

[0264] SEQ ID NO:48 is a heavy chain variable region (VH) for the 4-lBB agonist antibody 4B4-1-1 version 1.

[0265] SEQ ID NO:49 is a light chain variable region (VL) for the 4-lBB agonist antibody 4B4-1-1 version 1.

[0266] SEQ ID NO:50 is a heavy chain variable region (VH) for the 4-lBB agonist antibody 4B4-1-1 version 2.

[0267] SEQ ID NO:51 is a light chain variable region (VL) for the 4-lBB agonist antibody 4B4-1-1 version 2.

[0268] SEQ ID NO:52 is a heavy chain variable region (VH) for the 4-lBB agonist antibodyH39E3-2.

[0269] SEQ ID NO:53 is a light chain variable region (VL) for the 4-1BB agonist antibody H39E3-2.

[0270] SEQ ID NO:54 is the amino acid sequence of human OX40.

[0271] SEQ ID NO:55 is the amino acid sequence of murine OX40.

[0272] SEQ ID NO:56 is the heavy chain for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0273] SEQ ID NO:57 is the light chain for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0274] SEQ ID NO:58 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0275] SEQ ID NO:59 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0276] SEQ ID NO:60 is the heavy chain CDRl for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0277] SEQ ID NO:61 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0278] SEQ ID NO:62 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0279] SEQ ID NO:63 is the light chain CDRl for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0280] SEQ ID NO:64 is the light chain CDR2 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0281] SEQ ID NO:65 is the light chain CDR3 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).

[0282] SEQ ID NO:66 is the heavy chain for the OX40 agonist monoclonal antibody 11D4.

[0283] SEQ ID NO:67 is the light chain for the OX40 agonist monoclonal antibody 11D4.

[0284] SEQ ID NO:68 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 11D4.

[0285] SEQ ID NO:69 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 1 1D4.

[0286] SEQ ID NO: 70 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody 1 1D4.

[0287] SEQ ID NO:71 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody 1 1D4.

[0288] SEQ ID NO:72 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody 1 1D4.

[0289] SEQ ID NO:73 is the light chain CDR1 for the OX40 agonist monoclonal antibody 11D4.

[0290] SEQ ID NO:74 is the light chain CDR2 for the OX40 agonist monoclonal antibody 1 1D4.

[0291] SEQ ID NO:75 is the light chain CDR3 for the OX40 agonist monoclonal antibody 1 1D4.

[0292] SEQ ID NO:76 is the heavy chain for the OX40 agonist monoclonal antibody 18D8.

[0293] SEQ ID NO:77 is the light chain for the OX40 agonist monoclonal antibody 18D8.

[0294] SEQ ID NO:78 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 18D8.

[0295] SEQ ID NO:79 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 18D8.

[0296] SEQ ID NO:80 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody 18D8.

[0297] SEQ ID NO: 81 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody 18D8.

[0298] SEQ ID NO:82 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody18D8.

[0299] SEQ ID NO:83 is the light chain CDRl for the OX40 agonist monoclonal antibody 18D8.

[0300] SEQ ID NO:84 is the light chain CDR2 for the OX40 agonist monoclonal antibody 18D8.

[0301] SEQ ID NO:85 is the light chain CDR3 for the OX40 agonist monoclonal antibody 18D8.

[0302] SEQ ID NO:86 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody Hul 19-122.

[0303] SEQ ID NO:87 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody Hul 19-122.

[0304] SEQ ID NO:88 is the heavy chain CDRl for the OX40 agonist monoclonal antibody Hul 19-122.

[0305] SEQ ID NO:89 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody Hul 19-122.

[0306] SEQ ID NO:90 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody Hul 19-122.

[0307] SEQ ID NO:91 is the light chain CDRl for the OX40 agonist monoclonal antibody Hul 19-122.

[0308] SEQ ID NO:92 is the light chain CDR2 for the OX40 agonist monoclonal antibody Hul 19-122.

[0309] SEQ ID NO:93 is the light chain CDR3 for the OX40 agonist monoclonal antibody Hul 19-122.

[0310] SEQ ID NO:94 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody Hul 06-222.

[0311] SEQ ID NO:95 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody Hul06-222.

[0312] SEQ ID NO:96 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody Hul06-222.

[0313] SEQ ID NO:97 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody Hu 106-222.

[0314] SEQ ID NO:98 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody Hul06-222.

[0315] SEQ ID NO:99 is the light chain CDR1 for the OX40 agonist monoclonal antibody Hul06-222.

[0316] SEQ ID NO: 100 is the light chain CDR2 for the OX40 agonist monoclonal antibody Hul06-222.

[0317] SEQ ID NO: 101 is the light chain CDR3 for the OX40 agonist monoclonal antibody Hul06-222.

[0318] SEQ ID NO: 102 is an OX40 ligand (OX40L) amino acid sequence.

[0319] SEQ ID NO: 103 is a soluble portion of OX40L polypeptide.

[0320] SEQ ID NO: 104 is an alternative soluble portion of OX40L polypeptide.

[0321] SEQ ID NO: 105 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 008.

[0322] SEQ ID NO: 106 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 008.

[0323] SEQ ID NO: 107 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 01 1.

[0324] SEQ ID NO: 108 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 01 1.

[0325] SEQ ID NO: 109 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 021.

[0326] SEQ ID NO: 1 10 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 021.

[0327] SEQ ID NO: 111 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 023.

[0328] SEQ ID NO: 112 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 023.

[0329] SEQ ID NO: 113 is the heavy chain variable region (VH) for an OX40 agonist monoclonal antibody.

[0330] SEQ ID NO: 114 is the light chain variable region (VL) for an OX40 agonist monoclonal antibody.

[0331] SEQ ID NO: 115 is the heavy chain variable region (VH) for an OX40 agonist monoclonal antibody.

[0332] SEQ ID NO: 116 is the light chain variable region (VL) for an OX40 agonist monoclonal antibody.

[0333] SEQ ID NO: 117 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.

[0334] SEQ ID NO: 118 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.

[0335] SEQ ID NO: 119 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.

[0336] SEQ ID NO: 120 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.

[0337] SEQ ID NO: 121 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.

[0338] SEQ ID NO: 122 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.

[0339] SEQ ID NO: 123 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.

[0340] SEQ ID NO: 124 is the light chain variable region (VL) for a humanized OX40 agonistmonoclonal antibody.

[0341] SEQ ID NO: 125 is the heavy chain variable region (VH) for an OX40 agonist monoclonal antibody.

[0342] SEQ ID NO: 126 is the light chain variable region (VL) for an OX40 agonist monoclonal antibody.

[0343] SEQ ID NO: 127 is the amino acid sequence of human CD27.

[0344] SEQ ID NO: 128 is the amino acid sequence of macaque CD27.

[0345] SEQ ID NO: 129 is the heavy chain for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0346] SEQ ID NO: 130 is the light chain for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0347] SEQ ID NO: 131 is the heavy chain variable region (VH) for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0348] SEQ ID NO: 132 is the light chain variable region (VL) for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0349] SEQ ID NO: 133 is the heavy chain CDRl for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0350] SEQ ID NO: 134 is the heavy chain CDR2 for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0351] SEQ ID NO: 135 is the heavy chain CDR3 for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0352] SEQ ID NO: 136 is the light chain CDRl for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0353] SEQ ID NO: 137 is the light chain CDR2 for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0354] SEQ ID NO: 138 is the light chain CDR3 for the CD27 agonist monoclonal antibody varlilumab (CDX-1127).

[0355] SEQ ID NO: 139 is an CD27 ligand (CD70) amino acid sequence.

[0356] SEQ ID NO: 140 is a soluble portion of CD70 polypeptide.

[0357] SEQ ID NO: 141 is an alternative soluble portion of CD70 polypeptide.

[0358] SEQ ID NO: 142 is the amino acid sequence of human GITR (human tumor necrosis factor receptor superfamily member 18 (TNFRSF18) protein).

[0359] SEQ ID NO: 143 is the amino acid sequence of murine GITR (murine tumor necrosis factor receptor superfamily member 18 (TNFRSF18) protein).

[0360] SEQ ID NO: 144 is the amino acid sequence of the heavy chain variant HuN6C8 (glycosylated) of the 6C8 humanized GITR agonist monoclonal antibody, with an N (asparagine) in CDR2, corresponding to SEQ ID NO: 60 in U.S. Patent No. 7,812,135.

[0361] SEQ ID NO: 145 is the amino acid sequence of the heavy chain variant HuN6C8 (aglycosylated) of the 6C8 humanized GITR agonist monoclonal antibody, with an N(asparagine) in CDR2, corresponding to SEQ ID NO:61 in U.S. Patent No. 7,812, 135.

[0362] SEQ ID NO: 146 is the amino acid sequence of the heavy chain variant HuQ6C8 (glycosylated) of the 6C8 humanized GITR agonist monoclonal antibody, with an Q (glutamine) in CDR2, corresponding to SEQ ID NO: 62 in U.S. Patent No. 7,812,135.

[0363] SEQ ID NO: 147 is the amino acid sequence of the heavy chain variant HuQ6C8 (aglycosylated) of the 6C8 humanized GITR agonist monoclonal antibody, with an Q(glutamine) in CDR2, corresponding to SEQ ID NO:63 in U.S. Patent No. 7,812, 135.

[0364] SEQ ID NO: 148 is the amino acid sequence of the light chain of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:58 in U.S. Patent No.7,812,135.

[0365] SEQ ID NO: 149 is the amino acid sequence of the leader sequence that may optionally be included with the amino acid sequences of SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, or SEQ ID NO: 147 in GITR agonist monoclonal antibodies.

[0366] SEQ ID NO: 150 is the amino acid sequence of the leader sequence that may optionally be included with the amino acid sequence of SEQ ID NO: 148 in GITR agonist monoclonal antibodies.

[0367] SEQ ID NO: 151 is the amino acid sequence of the heavy chain variable region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO: l in U.S. Patent No. 7,812, 135.

[0368] SEQ ID NO: 152 is the amino acid sequence of the heavy chain variable region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:66 in U.S. Patent No. 7,812, 135.

[0369] SEQ ID NO: 153 is the amino acid sequence of the light chain variable region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:2 in U.S. Patent No. 7,812, 135.

[0370] SEQ ID NO: 154 is the amino acid sequence of the heavy chain CDR1 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:3 in U.S. Patent No. 7,812, 135.

[0371] SEQ ID NO: 155 is the amino acid sequence of the heavy chain CDR2 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:4 in U.S. Patent No. 7,812, 135.

[0372] SEQ ID NO: 156 is the amino acid sequence of the heavy chain CDR2 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO: 19 in U.S. Patent No. 7,812, 135.

[0373] SEQ ID NO: 157 is the amino acid sequence of the heavy chain CDR3 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:5 in U.S. Patent No. 7,812, 135.

[0374] SEQ ID NO: 158 is the amino acid sequence of the heavy chain CDR1 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:6 in U.S. Patent No. 7,812, 135.

[0375] SEQ ID NO: 159 is the amino acid sequence of the heavy chain CDR2 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:7 in U.S. Patent No. 7,812, 135.

[0376] SEQ ID NO: 160 is the amino acid sequence of the heavy chain CDR3 region of the 6C8 humanized GITR agonist monoclonal antibody, corresponding to SEQ ID NO:8 in U.S.Patent No. 7,812, 135.

[0377] SEQ ID NO: 161 is the amino acid sequence of the heavy chain variant HuN6C8 (glycosylated) of the 6C8 chimeric GITR agonist monoclonal antibody, with an N (asparagine) in CDR2, corresponding to SEQ ID NO:23 in U.S. Patent No. 7,812,135.

[0378] SEQ ID NO: 162 is the amino acid sequence of the heavy chain variant HuQ6C8 (aglycosylated) of the 6C8 chimeric GITR agonist monoclonal antibody, with an Q (glutamine) in CDR2, corresponding to SEQ ID NO:24 in U.S. Patent No. 7,812,135.

[0379] SEQ ID NO: 163 is the amino acid sequence of the light chain of the 6C8 chimeric GITR agonist monoclonal antibody, corresponding to SEQ ID NO:22 in U.S. Patent No.7,812,135.

[0380] SEQ ID NO: 164 is the amino acid sequence of the GITR agonist 36E5 heavy chain variable region from U.S. Patent No. 8,709,424.

[0381] SEQ ID NO: 165 is the amino acid sequence of the GITR agonist 36E5 light chain variable region from U.S. Patent No. 8,709,424.

[0382] SEQ ID NO: 166 is the amino acid sequence of the GITR agonist 3D6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0383] SEQ ID NO: 167 is the amino acid sequence of the GITR agonist 3D6 light chain variable region from U.S. Patent No. 8,709,424.

[0384] SEQ ID NO: 168 is the amino acid sequence of the GITR agonist 61G6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0385] SEQ ID NO: 169 is the amino acid sequence of the GITR agonist 61G6 light chain variable region from U.S. Patent No. 8,709,424.

[0386] SEQ ID NO: 170 is the amino acid sequence of the GITR agonist 6H6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0387] SEQ ID NO: 171 is the amino acid sequence of the GITR agonist 6H6 light chain variable region from U.S. Patent No. 8,709,424.

[0388] SEQ ID NO: 172 is the amino acid sequence of the GITR agonist 61F6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0389] SEQ ID NO: 173 is the amino acid sequence of the GITR agonist 61F6 light chain variable region from U.S. Patent No. 8,709,424.

[0390] SEQ ID NO: 174 is the amino acid sequence of the GITR agonist 1D8 heavy chain variable region from U.S. Patent No. 8,709,424.

[0391] SEQ ID NO: 175 is the amino acid sequence of the GITR agonist 1D8 light chain variable region from U.S. Patent No. 8,709,424.

[0392] SEQ ID NO: 176 is the amino acid sequence of the GITR agonist 17F10 heavy chain variable region from U.S. Patent No. 8,709,424.

[0393] SEQ ID NO: 177 is the amino acid sequence of the GITR agonist 17F10 light chain variable region from U.S. Patent No. 8,709,424.

[0394] SEQ ID NO: 178 is the amino acid sequence of the GITR agonist 35D8 heavy chain variable region from U.S. Patent No. 8,709,424.

[0395] SEQ ID NO: 179 is the amino acid sequence of the GITR agonist 35D8 light chain variable region from U.S. Patent No. 8,709,424.

[0396] SEQ ID NO: 180 is the amino acid sequence of the GITR agonist 49A1 heavy chain variable region from U.S. Patent No. 8,709,424.

[0397] SEQ ID NO: 181 is the amino acid sequence of the GITR agonist 49A1 light chain variable region from U.S. Patent No. 8,709,424.

[0398] SEQ ID NO: 182 is the amino acid sequence of the GITR agonist 9E5 heavy chain variable region from U.S. Patent No. 8,709,424.

[0399] SEQ ID NO: 183 is the amino acid sequence of the GITR agonist 9E5 light chain variable region from U.S. Patent No. 8,709,424.

[0400] SEQ ID NO: 184 is the amino acid sequence of the GITR agonist 31H6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0401] SEQ ID NO: 185 is the amino acid sequence of the GITR agonist 31H6 light chain variable region from U.S. Patent No. 8,709,424.

[0402] SEQ ID NO: 186 is the amino acid sequence of the humanized GITR agonist 36E5heavy chain variable region from U.S. Patent No. 8,709,424.

[0403] SEQ ID NO: 187 is the amino acid sequence of the humanized GITR agonist 36E5 light chain variable region from U.S. Patent No. 8,709,424.

[0404] SEQ ID NO: 188 is the amino acid sequence of the humanized GITR agonist 3D6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0405] SEQ ID NO: 189 is the amino acid sequence of the humanized GITR agonist 3D6 light chain variable region from U.S. Patent No. 8,709,424.

[0406] SEQ ID NO: 190 is the amino acid sequence of the humanized GITR agonist 61G6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0407] SEQ ID NO: 191 is the amino acid sequence of the humanized GITR agonist 61G6 light chain variable region from U.S. Patent No. 8,709,424.

[0408] SEQ ID NO: 192 is the amino acid sequence of the humanized GITR agonist 6H6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0409] SEQ ID NO: 193 is the amino acid sequence of the humanized GITR agonist 6H6 light chain variable region from U.S. Patent No. 8,709,424.

[0410] SEQ ID NO: 194 is the amino acid sequence of the humanized GITR agonist 61F6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0411] SEQ ID NO: 195 is the amino acid sequence of the humanized GITR agonist 61F6 light chain variable region from U.S. Patent No. 8,709,424.

[0412] SEQ ID NO: 196 is the amino acid sequence of the humanized GITR agonist 1D8 heavy chain variable region from U.S. Patent No. 8,709,424.

[0413] SEQ ID NO: 197 is the amino acid sequence of the humanized GITR agonist 1D8 light chain variable region from U.S. Patent No. 8,709,424.

[0414] SEQ ID NO: 198 is the amino acid sequence of the humanized GITR agonist 17F10 heavy chain variable region from U.S. Patent No. 8,709,424.

[0415] SEQ ID NO: 199 is the amino acid sequence of the humanized GITR agonist 17F10 light chain variable region from U.S. Patent No. 8,709,424.

[0416] SEQ ID NO:200 is the amino acid sequence of the humanized GITR agonist 35D8 heavy chain variable region from U.S. Patent No. 8,709,424.

[0417] SEQ ID NO:201 is the amino acid sequence of the humanized GITR agonist 35D8 light chain variable region from U.S. Patent No. 8,709,424.

[0418] SEQ ID NO:202 is the amino acid sequence of the humanized GITR agonist 49A1 heavy chain variable region from U.S. Patent No. 8,709,424.

[0419] SEQ ID NO:203 is the amino acid sequence of the humanized GITR agonist 49A1 light chain variable region from U.S. Patent No. 8,709,424.

[0420] SEQ ID NO:204 is the amino acid sequence of the humanized GITR agonist 9E5 heavy chain variable region from U.S. Patent No. 8,709,424.

[0421] SEQ ID NO:205 is the amino acid sequence of the humanized GITR agonist 9E5 light chain variable region from U.S. Patent No. 8,709,424.

[0422] SEQ ID NO:206 is the amino acid sequence of the humanized GITR agonist 31H6 heavy chain variable region from U.S. Patent No. 8,709,424.

[0423] SEQ ID NO:207 is the amino acid sequence of the humanized GITR agonist 31H6 light chain variable region from U.S. Patent No. 8,709,424.

[0424] SEQ ID NO:208 is the amino acid sequence of the GITR agonist 2155 variable heavy chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0425] SEQ ID NO:209 is the amino acid sequence of the GITR agonist 2155 variable light chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0426] SEQ ID NO:210 is the amino acid sequence of the GITR agonist 2155 humanized (HCl) heavy chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0427] SEQ ID NO:211 is the amino acid sequence of the GITR agonist 2155 humanized (HC2) heavy chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0428] SEQ ID NO:212 is the amino acid sequence of the GITR agonist 2155 humanized (HC3a) heavy chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0429] SEQ ID NO:213 is the amino acid sequence of the humanized (HC3b) GITR agonistheavy chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0430] SEQ ID NO:214 is the amino acid sequence of the humanized (HC4) GITR agonist heavy chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0431] SEQ ID NO:215 is the amino acid sequence of the 2155 humanized (LCI) GITR agonist light chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0432] SEQ ID NO:216 is the amino acid sequence of the 2155 humanized (LC2a) GITR agonist light chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0433] SEQ ID NO:217 is the amino acid sequence of the 2155 humanized (LC2b) GITR agonist light chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0434] SEQ ID NO:218 is the amino acid sequence of the 2155 humanized (LC3) GITR agonist light chain from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0435] SEQchain from U.S.

[0436] SEQchain from U.S.

[0437] SEQchain from U.S.

[0438] SEQchain from U.S.

[0439] SEQchain from U.S.

[0440] SEQchain from U.S.

[0441] SEQchain from U.S.

[0442] SEQchain from U.S.

[0443] SEQ ID NO:227 is the amino acid sequence of the GITR agonist 2155 heavy chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0444] SEQ ID NO:228 is the amino acid sequence of the GITR agonist 2155 heavy chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0445] SEQ ID NO:229 is the amino acid sequence of the GITR agonist 2155 heavy chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0446] SEQ ID NO:230 is the amino acid sequence of the GITR agonist 2155 light chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0447] SEQ ID NO:231 is the amino acid sequence of the GITR agonist 2155 light chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0448] SEQ ID NO:232 is the amino acid sequence of the GITR agonist 2155 light chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0449] SEQ ID NO:233 is the amino acid sequence of the GITR agonists 698 and 706 heavy chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0450] SEQ ID NO:234 is the amino acid sequence of the GITR agonists 698 and 706 heavy chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0451] SEQ ID NO:235 is the amino acid sequence of the GITR agonists 698 and 706 heavy chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0452] SEQ ID NO:236 is the amino acid sequence of the GITR agonist 698 light chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0453] SEQ ID NO:237 is the amino acid sequence of the GITR agonists 698, 706, 827, and 1649 light chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0454] SEQ ID NO:238 is the amino acid sequence of the GITR agonists 698, 706, 827, and 1649 light chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0455] SEQ ID NO:239 is the amino acid sequence of the GITR agonists 706, 827, and 1649 light chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0456] SEQ ID NO:240 is the amino acid sequence of the GITR agonists 827 and 1649heavy chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0457] SEQ ID NO:241 is the amino acid sequence of the GITR agonist 827 heavy chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0458] SEQ ID NO:242 is the amino acid sequence of the GITR agonist 1649 heavy chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0459] SEQ ID NO:243 is the amino acid sequence of the GITR agonist 1718 heavy chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0460] SEQ ID NO:244 is the amino acid sequence of the GITR agonist 1718 heavy chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0461] SEQ ID NO:245 is the amino acid sequence of the GITR agonist 1718 heavy chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0462] SEQ ID NO:246 is the amino acid sequence of the GITR agonist 1718 light chain CDR3 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0463] SEQ ID NO:247 is the amino acid sequence of the GITR agonist 1718 light chain CDR2 from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0464] SEQ ID NO:248 is the amino acid sequence of the GITR agonist 1718 light chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0465] SEQ ID NO:249 is the amino acid sequence of the GITR agonists 827 and 1649 heavy chain CDRl from U.S. Patent Application Publication No. US 2013 / 0108641 Al .

[0466] SEQ ID NO:250 is the amino acid sequence of the GITR agonist 1D7 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0467] SEQ ID NO:251 is the amino acid sequence of the GITR agonist 1D7 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0468] SEQ ID NO:252 is the amino acid sequence of the GITR agonist 1D7 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0469] SEQ ID NO:253 is the amino acid sequence of the GITR agonist 1D7 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0470] SEQ ID NO:254 is the amino acid sequence of the GITR agonist 1D7 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0471] SEQ ID NO:255 is the amino acid sequence of the GITR agonist 1D7 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0472] SEQ ID NO:256 is the amino acid sequence of the GITR agonist 1D7 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0473] SEQ ID NO:257 is the amino acid sequence of the GITR agonist 1D7 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0474] SEQ ID NO:258 is the amino acid sequence of the GITR agonist 1D7 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0475] SEQ ID NO:259 is the amino acid sequence of the GITR agonist 1D7 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0476] SEQ ID NO:260 is the amino acid sequence of the GITR agonist 33C9 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0477] SEQ ID NO:261 is the amino acid sequence of the GITR agonist 33C9 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0478] SEQ ID NO:262 is the amino acid sequence of the GITR agonist 33C9 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0479] SEQ ID NO:263 is the amino acid sequence of the GITR agonist 33C9 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0480] SEQ ID NO:264 is the amino acid sequence of the GITR agonist 33C9 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0481] SEQ ID NO:265 is the amino acid sequence of the GITR agonist 33C9 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0482] SEQ ID NO:266 is the amino acid sequence of the GITR agonist 33C9 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0483] SEQ ID NO:267 is the amino acid sequence of the GITR agonist 33C9 light chainCDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0484] SEQ ID NO:268 is the amino acid sequence of the GITR agonist 33C9 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0485] SEQ ID NO:269 is the amino acid sequence of the GITR agonist 33C9 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0486] SEQ ID NO:270 is the amino acid sequence of the GITR agonist 33F6 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0487] SEQ ID NO:271 is the amino acid sequence of the GITR agonist 33F6 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0488] SEQ ID NO:272 is the amino acid sequence of the GITR agonist 33F6 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0489] SEQ ID NO:273 is the amino acid sequence of the GITR agonist 33F6 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0490] SEQ ID NO:274 is the amino acid sequence of the GITR agonist 33F6 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0491] SEQ ID NO:275 is the amino acid sequence of the GITR agonist 33F6 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0492] SEQ ID NO:276 is the amino acid sequence of the GITR agonist 33F6 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0493] SEQ ID NO:277 is the amino acid sequence of the GITR agonist 33F6 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0494] SEQ ID NO:278 is the amino acid sequence of the GITR agonist 33F6 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0495] SEQ ID NO:279 is the amino acid sequence of the GITR agonist 33F6 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0496] SEQ ID NO:280 is the amino acid sequence of the GITR agonist 34G4 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0497] SEQ ID NO:281 is the amino acid sequence of the GITR agonist 34G4 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0498] SEQ ID NO:282 is the amino acid sequence of the GITR agonist 34G4 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0499] SEQ ID NO:283 is the amino acid sequence of the GITR agonist 34G4 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0500] SEQ ID NO:284 is the amino acid sequence of the GITR agonist 34G4 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0501] SEQ ID NO:285 is the amino acid sequence of the GITR agonist 34G4 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0502] SEQ ID NO:286 is the amino acid sequence of the GITR agonist 34G4 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0503] SEQ ID NO:287 is the amino acid sequence of the GITR agonist 34G4 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0504] SEQ ID NO:288 is the amino acid sequence of the GITR agonist 34G4 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0505] SEQ ID NO:289 is the amino acid sequence of the GITR agonist 34G4 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0506] SEQ ID NO:290 is the amino acid sequence of the GITR agonist 35B 10 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0507] SEQ ID N0.291 is the amino acid sequence of the GITR agonist 35B 10 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0508] SEQ ID NO:292 is the amino acid sequence of the GITR agonist 35B 10 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0509] SEQ ID NO:293 is the amino acid sequence of the GITR agonist 35B 10 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0510] SEQ ID NO:294 is the amino acid sequence of the GITR agonist 35B 10 heavy chainCDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0511] SEQ ID NO:295 is the amino acid sequence of the GITR agonist 35B 10 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0512] SEQ ID NO:296 is the amino acid sequence of the GITR agonist 35B 10 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0513] SEQ ID NO:297 is the amino acid sequence of the GITR agonist 35B 10 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0514] SEQ ID NO:298 is the amino acid sequence of the GITR agonist 35B 10 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0515] SEQ ID NO:299 is the amino acid sequence of the GITR agonist 35B 10 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0516] SEQ ID NO:300 is the amino acid sequence of the GITR agonist 41E11 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0517] SEQ ID NO:301 is the amino acid sequence of the GITR agonist 41E11 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0518] SEQ ID NO:302 is the amino acid sequence of the GITR agonist 41E11 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0519] SEQ ID NO:303 is the amino acid sequence of the GITR agonist 41E11 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0520] SEQ ID NO:304 is the amino acid sequence of the GITR agonist 41E11 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0521] SEQ ID NO:305 is the amino acid sequence of the GITR agonist 41E11 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0522] SEQ ID NO:306 is the amino acid sequence of the GITR agonist 41E11 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0523] SEQ ID NO:307 is the amino acid sequence of the GITR agonist 41E11 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0524] SEQ ID NO:308 is the amino acid sequence of the GITR agonist 41E11 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0525] SEQ ID NO:309 is the amino acid sequence of the GITR agonist 41E1 1 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0526] SEQ ID NO:310 is the amino acid sequence of the GITR agonist 41G5 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0527] SEQ ID NO:311 is the amino acid sequence of the GITR agonist 41G5 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0528] SEQ ID NO:312 is the amino acid sequence of the GITR agonist 41G5 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0529] SEQ ID NO:313 is the amino acid sequence of the GITR agonist 41G5 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0530] SEQ ID NO:314 is the amino acid sequence of the GITR agonist 41G5 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0531] SEQ ID NO:315 is the amino acid sequence of the GITR agonist 41G5 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0532] SEQ ID NO:316 is the amino acid sequence of the GITR agonist 41G5 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0533] SEQ ID NO:317 is the amino acid sequence of the GITR agonist 41G5 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0534] SEQ ID NO:318 is the amino acid sequence of the GITR agonist 41G5 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0535] SEQ ID NO:319 is the amino acid sequence of the GITR agonist 41G5 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0536] SEQ ID NO:320 is the amino acid sequence of the GITR agonist 42A1 1 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0537] SEQ ID NO:321 is the amino acid sequence of the GITR agonist 42A11 light chainfrom U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0538] SEQ ID NO:322 is the amino acid sequence of the GITR agonist 42A11 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0539] SEQ ID NO:323 is the amino acid sequence of the GITR agonist 42A11 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0540] SEQ ID NO:324 is the amino acid sequence of the GITR agonist 42A11 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0541] SEQ ID NO:325 is the amino acid sequence of the GITR agonist 42A11 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0542] SEQ ID NO:326 is the amino acid sequence of the GITR agonist 42A11 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0543] SEQ ID NO:327 is the amino acid sequence of the GITR agonist 42A11 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0544] SEQ ID NO:328 is the amino acid sequence of the GITR agonist 42A11 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0545] SEQ ID NO:329 is the amino acid sequence of the GITR agonist 42A11 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0546] SEQ ID NO:330 is the amino acid sequence of the GITR agonist 44C1 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0547] SEQ ID NO:331 is the amino acid sequence of the GITR agonist 44C1 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0548] SEQ ID NO:332 is the amino acid sequence of the GITR agonist 44C1 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0549] SEQ ID NO:333 is the amino acid sequence of the GITR agonist 44C1 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0550] SEQ ID NO:334 is the amino acid sequence of the GITR agonist 44C1 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0551] SEQ ID NO:335 is the amino acid sequence of the GITR agonist 44C1 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0552] SEQ ID NO:336 is the amino acid sequence of the GITR agonist 44C 1 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0553] SEQ ID NO:337 is the amino acid sequence of the GITR agonist 44C1 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0554] SEQ ID NO:338 is the amino acid sequence of the GITR agonist 44C1 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0555] SEQ ID NO:339 is the amino acid sequence of the GITR agonist 44C1 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0556] SEQ ID NO:340 is the amino acid sequence of the GITR agonist 45A8 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0557] SEQ ID NO:341 is the amino acid sequence of the GITR agonist 45A8 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0558] SEQ ID NO:342 is the amino acid sequence of the GITR agonist 45A8 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0559] SEQ ID NO:343 is the amino acid sequence of the GITR agonist 45A8 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0560] SEQ ID NO:344 is the amino acid sequence of the GITR agonist 45A8 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0561] SEQ ID NO:345 is the amino acid sequence of the GITR agonist 45A8 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0562] SEQ ID NO:346 is the amino acid sequence of the GITR agonist 45A8 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0563] SEQ ID NO:347 is the amino acid sequence of the GITR agonist 45A8 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0564] SEQ ID NO:348 is the amino acid sequence of the GITR agonist 45A8 light chainCDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0565] SEQ ID NO:349 is the amino acid sequence of the GITR agonist 45A8 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0566] SEQ ID NO:350 is the amino acid sequence of the GITR agonist 46E11 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0567] SEQ ID NO:351 is the amino acid sequence of the GITR agonist 46E11 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0568] SEQ ID NO:352 is the amino acid sequence of the GITR agonist 46E11 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0569] SEQ ID NO:353 is the amino acid sequence of the GITR agonist 46E11 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0570] SEQ ID NO:354 is the amino acid sequence of the GITR agonist 46E11 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0571] SEQ ID NO:355 is the amino acid sequence of the GITR agonist 46E11 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0572] SEQ ID NO:356 is the amino acid sequence of the GITR agonist 46E11 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0573] SEQ ID NO:357 is the amino acid sequence of the GITR agonist 46E11 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0574] SEQ ID NO:358 is the amino acid sequence of the GITR agonist 46E11 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0575] SEQ ID NO:359 is the amino acid sequence of the GITR agonist 46E11 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0576] SEQ ID NO:360 is the amino acid sequence of the GITR agonist 48H12 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0577] SEQ ID NO:361 is the amino acid sequence of the GITR agonist 48H12 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0578] SEQ ID NO:362 is the amino acid sequence of the GITR agonist 48H12 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0579] SEQ ID NO:363 is the amino acid sequence of the GITR agonist 48H12 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0580] SEQ ID NO:364 is the amino acid sequence of the GITR agonist 48H12 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0581] SEQ ID NO:365 is the amino acid sequence of the GITR agonist 48H12 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0582] SEQ ID NO:366 is the amino acid sequence of the GITR agonist 48H12 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0583] SEQ ID NO:367 is the amino acid sequence of the GITR agonist 48H12 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0584] SEQ ID NO:368 is the amino acid sequence of the GITR agonist 48H12 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0585] SEQ ID NO:369 is the amino acid sequence of the GITR agonist 48H12 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0586] SEQ ID NO:370 is the amino acid sequence of the GITR agonist 48H7 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0587] SEQ ID NO:371 is the amino acid sequence of the GITR agonist 48H7 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0588] SEQ ID NO:372 is the amino acid sequence of the GITR agonist 48H7 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0589] SEQ ID NO:373 is the amino acid sequence of the GITR agonist 48H7 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0590] SEQ ID NO:374 is the amino acid sequence of the GITR agonist 48H7 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0591] SEQ ID NO:375 is the amino acid sequence of the GITR agonist 48H7 heavy chainCDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0592] SEQ ID NO:376 is the amino acid sequence of the GITR agonist 48H7 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0593] SEQ ID NO:377 is the amino acid sequence of the GITR agonist 48H7 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0594] SEQ ID NO:378 is the amino acid sequence of the GITR agonist 48H7 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0595] SEQ ID NO:379 is the amino acid sequence of the GITR agonist 48H7 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0596] SEQ ID NO:380 is the amino acid sequence of the GITR agonist 49D9 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0597] SEQ ID NO:381 is the amino acid sequence of the GITR agonist 49D9 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0598] SEQ ID NO:382 is the amino acid sequence of the GITR agonist 49D9 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0599] SEQ ID NO:383 is the amino acid sequence of the GITR agonist 49D9 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0600] SEQ ID NO:384 is the amino acid sequence of the GITR agonist 49D9 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0601] SEQ ID NO:385 is the amino acid sequence of the GITR agonist 49D9 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0602] SEQ ID NO:386 is the amino acid sequence of the GITR agonist 49D9 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0603] SEQ ID NO:387 is the amino acid sequence of the GITR agonist 49D9 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0604] SEQ ID NO:388 is the amino acid sequence of the GITR agonist 49D9 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0605] SEQ ID NO:389 is the amino acid sequence of the GITR agonist 49D9 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0606] SEQ ID NO:390 is the amino acid sequence of the GITR agonist 49E2 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0607] SEQ ID NO:391 is the amino acid sequence of the GITR agonist 49E2 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0608] SEQ ID NO:392 is the amino acid sequence of the GITR agonist 49E2 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0609] SEQ ID NO:393 is the amino acid sequence of the GITR agonist 49E2 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0610] SEQ ID NO:394 is the amino acid sequence of the GITR agonist 49E2 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0611] SEQ ID NO:395 is the amino acid sequence of the GITR agonist 49E2 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0612] SEQ ID NO:396 is the amino acid sequence of the GITR agonist 49E2 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0613] SEQ ID NO:397 is the amino acid sequence of the GITR agonist 49E2 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0614] SEQ ID NO:398 is the amino acid sequence of the GITR agonist 49E2 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0615] SEQ ID NO:399 is the amino acid sequence of the GITR agonist 49E2 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0616] SEQ ID NO:400 is the amino acid sequence of the GITR agonist 48A9 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0617] SEQ ID NO:401 is the amino acid sequence of the GITR agonist 48A9 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0618] SEQ ID NO:402 is the amino acid sequence of the GITR agonist 48A9 variable heavychain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0619] SEQ ID NO:403 is the amino acid sequence of the GITR agonist 48A9 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0620] SEQ ID NO:404 is the amino acid sequence of the GITR agonist 48A9 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0621] SEQ ID NO:405 is the amino acid sequence of the GITR agonist 48A9 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0622] SEQ ID NO:406 is the amino acid sequence of the GITR agonist 48A9 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0623] SEQ ID NO:407 is the amino acid sequence of the GITR agonist 48A9 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0624] SEQ ID NO:408 is the amino acid sequence of the GITR agonist 48A9 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0625] SEQ ID NO:409 is the amino acid sequence of the GITR agonist 48A9 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0626] SEQ ID NO:410 is the amino acid sequence of the GITR agonist 5H7 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0627] SEQ ID NO:411 is the amino acid sequence of the GITR agonist 5H7 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0628] SEQ ID NO:412 is the amino acid sequence of the GITR agonist 5H7 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0629] SEQ ID NO:413 is the amino acid sequence of the GITR agonist 5H7 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0630] SEQ ID NO:414 is the amino acid sequence of the GITR agonist 5H7 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0631] SEQ ID NO:415 is the amino acid sequence of the GITR agonist 5H7 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0632] SEQ ID NO:416 is the amino acid sequence of the GITR agonist 5H7 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0633] SEQ ID NO:417 is the amino acid sequence of the GITR agonist 5H7 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0634] SEQ ID NO:418 is the amino acid sequence of the GITR agonist 5H7 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0635] SEQ ID NO:419 is the amino acid sequence of the GITR agonist 5H7 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0636] SEQ ID NO:420 is the amino acid sequence of the GITR agonist 7A10 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0637] SEQ ID NO:421 is the amino acid sequence of the GITR agonist 7A10 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0638] SEQ ID NO:422 is the amino acid sequence of the GITR agonist 7A10 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0639] SEQ ID NO:423 is the amino acid sequence of the GITR agonist 7A10 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0640] SEQ ID NO:424 is the amino acid sequence of the GITR agonist 7A10 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0641] SEQ ID NO:425 is the amino acid sequence of the GITR agonist 7A10 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0642] SEQ ID NO:426 is the amino acid sequence of the GITR agonist 7A10 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0643] SEQ ID NO:427 is the amino acid sequence of the GITR agonist 7A10 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0644] SEQ ID NO:428 is the amino acid sequence of the GITR agonist 7A10 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0645] SEQ ID NO:429 is the amino acid sequence of the GITR agonist 7A10 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0646] SEQ ID NO:430 is the amino acid sequence of the GITR agonist 9H6 heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0647] SEQ ID NO:431 is the amino acid sequence of the GITR agonist 9H6 light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0648] SEQ ID NO:432 is the amino acid sequence of the GITR agonist 9H6 variable heavy chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0649] SEQ ID NO:433 is the amino acid sequence of the GITR agonist 9H6 variable light chain from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0650] SEQ ID NO:434 is the amino acid sequence of the GITR agonist 9H6 heavy chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0651] SEQ ID NO:435 is the amino acid sequence of the GITR agonist 9H6 heavy chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0652] SEQ ID NO:436 is the amino acid sequence of the GITR agonist 9H6 heavy chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0653] SEQ ID NO:437 is the amino acid sequence of the GITR agonist 9H6 light chain CDR1 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0654] SEQ ID NO:438 is the amino acid sequence of the GITR agonist 9H6 light chain CDR2 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0655] SEQ ID NO:439 is the amino acid sequence of the GITR agonist 9H6 light chain CDR3 from U.S. Patent Application Publication No. US 2015 / 0064204 Al .

[0656] SEQ ID NO:440 is an GITR ligand (GITRL) amino acid sequence.

[0657] SEQ ID NO:441 is a soluble portion of GITRL polypeptide.

[0658] SEQ ID NO:442 is the amino acid sequence of human HVEM (CD270).

[0659] SEQ ID NO:443 is a HVEM ligand (LIGHT) amino acid sequence.

[0660] SEQ ID NO:444 is a soluble portion of LIGHT polypeptide.

[0661] SEQ ID NO:445 is an alternative soluble portion of LIGHT polypeptide.

[0662] SEQ ID NO:446 is an alternative soluble portion of LIGHT polypeptide.

[0663] SEQ ID NO:447 is the amino acid sequence of human CD95 isoform 1.

[0664] SEQ ID NO:448 is the amino acid sequence of human CD95 isoform 2.

[0665] SEQ ID NO:449 is the amino acid sequence of human CD95 isoform 3.

[0666] SEQ ID NO:450 is the amino acid sequence of human CD95 isoform 4.

[0667] SEQ ID NO:451 is the heavy chain variable region (VH) for the CD95 agonist monoclonal antibody E09.

[0668] SEQ ID NO:452 is the light chain variable region (VL) for the CD95 agonist monoclonal antibody E09.

[0669] SEQ ID NO:453 is the heavy chain CDRl for the CD95 agonist monoclonal antibodyE09.

[0670] SEQ ID NO:454 is the heavy chain CDR2 for the CD95 agonist monoclonal antibodyE09.

[0671] SEQ ID NO:455 is the heavy chain CDR3 for the CD95 agonist monoclonal antibodyE09.

[0672] SEQ ID NO:456 is the light chain CDRl for the CD95 agonist monoclonal antibodyE09.

[0673] SEQ ID N0.457 is the light chain CDR2 for the CD95 agonist monoclonal antibodyE09.

[0674] SEQ ID NO:458 is the light chain CDR3 for the CD95 agonist monoclonal antibodyE09.

[0675] SEQ ID NO:459 is a CD95 ligand (CD95L) amino acid sequence.

[0676] SEQ ID NO:460 is a soluble portion of CD95L polypeptide.

[0677] SEQ ID NO:461 is an alternative soluble portion of CD95L polypeptide.

[0678] SEQ ID NO:462 is an alternative soluble portion of CD95L polypeptide.

[0679] SEQ ID NO:463 is the heavy chain amino acid sequence of the PD-1 inhibitor nivolumab.

[0680] SEQ ID NO:464 is the light chain amino acid sequence of the PD-1 inhibitor nivolumab.

[0681] SEQ ID NO:465 is the heavy chain variable region (VH) amino acid sequence of the PD-1 inhibitor nivolumab.

[0682] SEQ ID NO:466 is the light chain variable region (VL) amino acid sequence of the PD-1 inhibitor nivolumab.

[0683] SEQ ID NO:467 is the heavy chain CDRl amino acid sequence of the PD-1 inhibitor nivolumab.

[0684] SEQ ID NO:468 is the heavy chain CDR2 amino acid sequence of the PD-1 inhibitor nivolumab.

[0685] SEQ ID NO:469 is the heavy chain CDR3 amino acid sequence of the PD-1 inhibitor nivolumab.

[0686] SEQ ID NO:470 is the light chain CDRl amino acid sequence of the PD-1 inhibitor nivolumab.

[0687] SEQ ID NO:471 is the light chain CDR2 amino acid sequence of the PD-1 inhibitor nivolumab.

[0688] SEQ ID NO:472 is the light chain CDR3 amino acid sequence of the PD-1 inhibitor nivolumab.

[0689] SEQ ID N0.473 is the heavy chain amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0690] SEQ ID NO:474 is the light chain amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0691] SEQ ID NO:475 is the heavy chain variable region (VH) amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0692] SEQ ID NO:476 is the light chain variable region (VL) amino acid sequence of thePD-1 inhibitor pembrolizumab.

[0693] SEQ ID NO:477 is the heavy chain CDRl amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0694] SEQ ID NO:478 is the heavy chain CDR2 amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0695] SEQ ID NO:479 is the heavy chain CDR3 amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0696] SEQ ID NO:480 is the light chain CDRl amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0697] SEQ ID NO:481 is the light chain CDR2 amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0698] SEQ ID NO:482 is the light chain CDR3 amino acid sequence of the PD-1 inhibitor pembrolizumab.

[0699] SEQ ID NO:483 is the heavy chain amino acid sequence of the PD-L1 inhibitor durvalumab.

[0700] SEQ ID NO:484 is the light chain amino acid sequence of the PD-L1 inhibitor durvalumab.

[0701] SEQ ID N0.485 is the heavy chain variable region (VH) amino acid sequence of the PD-L1 inhibitor durvalumab.

[0702] SEQ ID NO:486 is the light chain variable region (VL) amino acid sequence of the PD-L1 inhibitor durvalumab.

[0703] SEQ ID NO:487 is the heavy chain CDRl amino acid sequence of the PD-L1 inhibitor durvalumab.

[0704] SEQ ID NO:488 is the heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor durvalumab.

[0705] SEQ ID NO:489 is the heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor durvalumab.

[0706] SEQ ID NO:490 is the light chain CDRl amino acid sequence of the PD-Ll inhibitor durvalumab.

[0707] SEQ ID NO:491 is the light chain CDR2 amino acid sequence of the PD-Ll inhibitor durvalumab.

[0708] SEQ ID NO.492 is the light chain CDR3 amino acid sequence of the PD-Ll inhibitor durvalumab.

[0709] SEQ ID NO:493 is the heavy chain amino acid sequence of the PD-Ll inhibitor avelumab.

[0710] SEQ ID NO:494 is the light chain amino acid sequence of the PD-Ll inhibitor avelumab.

[0711] SEQ ID NO:495 is the heavy chain variable region (VH) amino acid sequence of the PD-Ll inhibitor avelumab.

[0712] SEQ ID NO:496 is the light chain variable region (VL) amino acid sequence of the PD-Ll inhibitor avelumab.

[0713] SEQ ID NO:497 is the heavy chain CDRl amino acid sequence of the PD-Ll inhibitor avelumab.

[0714] SEQ ID NO:498 is the heavy chain CDR2 amino acid sequence of the PD-Ll inhibitor avelumab.

[0715] SEQ ID NO:499 is the heavy chain CDR3 amino acid sequence of the PD-Ll inhibitor avelumab.

[0716] SEQ ID NO:500 is the light chain CDRl amino acid sequence of the PD-Ll inhibitor avelumab.

[0717] SEQ ID NO:501 is the light chain CDR2 amino acid sequence of the PD-Ll inhibitor avelumab.

[0718] SEQ ID NO:502 is the light chain CDR3 amino acid sequence of the PD-Ll inhibitor avelumab.

[0719] SEQ ID NO:503 is the heavy chain amino acid sequence of the PD-Ll inhibitoratezolizumab.

[0720] SEQ ID NO:504 is the light chain amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0721] SEQ ID NO:505 is the heavy chain variable region (VH) amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0722] SEQ ID NO:506 is the light chain variable region (VL) amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0723] SEQ ID NO:507 is the heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0724] SEQ ID NO:508 is the heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0725] SEQ ID NO:509 is the heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0726] SEQ ID NO:510 is the light chain CDR1 amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0727] SEQ ID NO:511 is the light chain CDR2 amino acid sequence of the PD-L1 inhibitor atezolizumab.

[0728] SEQ ID NO:512 is the light chain CDR3 amino acid sequence of the PD-L1 inhibitor atezolizumab.DETAILED DESCRIPTION OF THE INVENTION

[0729] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference in their entireties.Definitions

[0730] The terms "co-administration," "co-administering," "administered in combination with," "administering in combination with," "simultaneous," and "concurrent," as used herein, encompass administration of two or more active pharmaceutical ingredients (in a preferred embodiment of the present invention, for example, at least one TNFRSF agonist and a pluralityof TILs) to a subject so that both active pharmaceutical ingredients and / or their metabolites are present in the subject at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which two or more active pharmaceutical ingredients are present. Simultaneous administration in separate compositions and administration in a composition in which both agents are present are preferred.

[0731] The term "rapid expansion" means an increase in the number of antigen-specific TILs of at least about 3-fold (or 4-, 5-, 6-, 7-, 8-, or 9-fold) over a period of a week, more preferably at least about 10-fold (or 20-, 30-, 40-, 50-, 60-, 70-, 80-, or 90-fold) over a period of a week, or most preferably at least about 100-fold over a period of a week. A number of rapid expansion protocols are described herein.

[0732] By "tumor infiltrating lymphocytes" or "TILs" herein is meant a population of cells originally obtained as white blood cells that have left the bloodstream of a subject and migrated into a tumor. TILs include, but are not limited to, CD8+cytotoxic T cells (lymphocytes), Thl and Thl7 CD4+T cells, natural killer cells, dendritic cells and Ml macrophages. TILs include both primary and secondary TILs. "Primary TILs" are those that are obtained from patient tissue samples as outlined herein (sometimes referred to as "freshly harvested"), and "secondary TILs" are any TIL cell populations that have been expanded or proliferated as discussed herein, including, but not limited to bulk TILs and expanded TILs ("REP TILs" or "post-REP TILs").

[0733] By "population of cells" (including TILs) herein is meant a number of cells that share common traits. In general, populations generally range from 1 X 106to 1 X 1010in number, with different TIL populations comprising different numbers. For example, initial growth of primary TILs in the presence of IL-2 results in a population of bulk TILs of roughly 1 x 108cells. REP expansion is generally done to provide populations of 1.5χ109to 1.5χ1010cells for infusion.

[0734] The term "central memory T cell" refers to a subset of T cells that in the human are CD45R0+ and constitutively express CCR7 (CCR7M) and CD62L (CD62M). The surface phenotype of central memory T cells also includes TCR, CD3, CD127 (IL-7R), and IL- 15R. Transcription factors for central memory T cells include BCL-6, BCL-6B, MBD2, and BMI1. Central memory T cells primarily secret IL-2 and CD40L as effector molecules afterTCR triggering. Central memory T cells are predominant in the CD4 compartment in blood, and in the human are proportionally enriched in lymph nodes and tonsils.

[0735] The term "anti-CD3 antibody" refers to an antibody or variant thereof, e.g., a monoclonal antibody and including human, humanized, chimeric or murine antibodies which are directed against the CD3 receptor in the T cell antigen receptor of mature T cells. Anti-CD3 antibodies include OKT-3, also known as muromonab. Anti-CD3 antibodies also include the UHCT1 clone, also known as T3 and CD3s. Other anti-CD3 antibodies include, for example, otelixizumab, teplizumab, and visilizumab.

[0736] The term "OKT-3" (also referred to herein as "OKT3") refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng / mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. The amino acid sequences of the heavy and light chains of muromonab are given in Table 1 (SEQ ID NO: 1 and SEQ ID NO:2).TABLE 1. Amino acid sequences of muromonab.Identifier Sequence (One-Letter Amino Acid Symbols)SEQ ID NO: 1 QVQLQQSGAE LARPGASVKM SCKASGYTFT RYTMHWVKQR PGQGLEWIGY INPSRGYTNY 60 Muromonab heavy NQKFKDKATL TTDKSSSTAY MQLSSLTSED SAVYYCARYY DDHYCLDYWG QGTTLTVSSA 120 chain KTTAPSVYPL APVCGGTTGS SVTLGCLVKG YFPEPVTLTW NSGSLSSGVH TFPAVLQSDL 180YTLSSSVTVT SSTWPSQSIT CNVAHPASST KVDKKIEPRP KSCDKTHTCP PCPAPELLGG 240PSVFLFPPKP KDTLMISRTP EVTCVWDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300STYRWSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE 360LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 420QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450SEQ ID NO: 2 QIVLTQSPAI MSASPGEKVT MTCSASSSVS YMNWYQQKSG TSPKRWIYDT SKLASGVPAH 60 Muromonab light FRGSGSGTSY SLTISGMEAE DAATYYCQQW SSNPFTFGSG TKLEINRADT APTVSIFPPS 120 chain SEQLTSGGAS WCFLNNFYP KDINVKWKID GSERQNGVLN SWTDQDSKDS TYSMSSTLTL 180TKDEYERHNS YTCEATHKTS TSPIVKSFNR NEC 213

[0737] The term "IL-2" (also referred to herein as "IL2") refers to the T cell growth factor known as interleukin-2, and includes all forms of IL-2 including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL-2 is described, e.g., in Nelson, J. Immunol. 2004, 172, 3983-88 and Malek, Annu. Rev. Immunol. 2008, 26, 453-79, the disclosures of which are incorporated by reference herein. The amino acid sequence of recombinant human IL-2 suitable for use in the invention is given in Table 2 (SEQID NO:3). For example, the term IL-2 encompasses human, recombinant forms of IL-2 such as aldesleukin (PROLEUKIN, available commercially from multiple suppliers in 22 million R7 per single use vials), as well as the form of recombinant IL-2 commercially supplied by CellGenix, Inc., Portsmouth, NH, USA (CELLGRO GMP) or ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-209-b) and other commercial equivalents from other vendors. Aldesleukin (des-alanyl-1, serine-125 human IL-2) is a nonglycosylated human recombinant form of IL-2 with a molecular weight of approximately 15 kDa. The amino acid sequence of aldesleukin suitable for use in the invention is given in Table 2 (SEQ ID NO:4). The term IL-2 also encompasses pegylated forms of IL-2, as described herein, including the pegylated IL2 prodrug NKTR-214, available from Nektar Therapeutics, South San Francisco, CA, USA. NKTR-214 and pegylated IL-2 suitable for use in the invention is described in U.S. Patent Application Publication No. US 2014 / 0328791 Al and International Patent Application Publication No. WO 2012 / 065086 Al, the disclosures of which are incorporated by reference herein. Alternative forms of conjugated IL-2 suitable for use in the invention are described in U.S. Patent Nos. 4,766,106, 5,206,344, 5,089,261 and 4902,502, the disclosures of which are incorporated by reference herein. Formulations of IL-2 suitable for use in the invention are described in U.S. Patent No. 6,706,289, the disclosure of which is incorporated by reference herein.TABLE 2. Amino acid sequences of interleukins.

[0738] The term "IL-4" (also referred to herein as "IL4") refers to the cytokine known as interleukin 4, which is produced by Th2 T cells and by eosinophils, basophils, and mast cells. IL-4 regulates the differentiation of naive helper T cells (ThO cells) to Th2 T cells. Steinke and Borish, Respir. Res. 2001, 2, 66-70. Upon activation by IL-4, Th2 T cells subsequently produce additional IL-4 in a positive feedback loop. IL-4 also stimulates B cell proliferation and class II MHC expression, and induces class switching to IgE and IgGi expression from B cells.Recombinant human IL-4 suitable for use in the invention is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-21 1) and ThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-15recombinant protein, Cat. No. Gibco CTP0043). The amino acid sequence of recombinant human IL-4 suitable for use in the invention is given in Table 2 (SEQ ID NO:5).

[0739] The term "IL-7" (also referred to herein as "IL7") refers to a glycosylated tissue- derived cytokine known as interleukin 7, which may be obtained from stromal and epithelial cells, as well as from dendritic cells. Fry and Mackall, Blood 2002, 99, 3892-904. IL-7 can stimulate the development of T cells. IL-7 binds to the IL-7 receptor, a heterodimer consisting of IIL-7 receptor alpha and common gamma chain receptor, which in a series of signals important for T cell development within the thymus and survival within the periphery. Recombinant human IL-7 suitable for use in the invention is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-254) and ThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-7 recombinant protein, Cat. No. Gibco PHC0071). The amino acid sequence of recombinant human IL-7 suitable for use in the invention is given in Table 2 (SEQ ID NO:6).

[0740] The term "IL-15" (also referred to herein as "IL15") refers to the T cell growth factor known as interleukin-15, and includes all forms of IL-15 including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL- 15 is described, e.g., in Fehniger and Caligiuri, Blood 2001, 97, 14-32, the disclosure of which is incorporated by reference herein. IL-15 shares β and γ signaling receptor subunits with IL-2. Recombinant human IL-15 is a single, non-glycosylated polypeptide chain containing 1 14 amino acids (and an N-terminal methionine) with a molecular mass of 12.8 kDa. Recombinant human IL-15 is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-230-b) and ThermoFisher Scientific, Inc.,Waltham, MA, USA (human IL-15 recombinant protein, Cat. No. 34-8159-82). The amino acid sequence of recombinant human IL-15 suitable for use in the invention is given in Table 2 (SEQ ID NO:7).

[0741] The term "IL-21" (also referred to herein as "IL21") refers to the pleiotropic cytokine protein known as interleukin-21, and includes all forms of IL-21 including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL-21 is described, e.g., in Spolski and Leonard, Nat. Rev. Drug. Disc. 2014, 13, 379- 95, the disclosure of which is incorporated by reference herein. IL-21 is primarily produced by natural killer T cells and activated human CD4+T cells. Recombinant human IL-21 is a single, non-glycosylated polypeptide chain containing 132 amino acids with a molecular mass of 15.4 kDa. Recombinant human IL-21 is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-408-b) andThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-21 recombinant protein, Cat. No. 14-8219-80). The amino acid sequence of recombinant human IL-21 suitable for use in the invention is given in Table 2 (SEQ ID NO: 8).

[0742] The term "in vivo" refers to an event that takes place in a mammalian subject's body.

[0743] The term "ex vivo" refers to an event that takes place outside of a mammalian subject's body, in an artificial environment.

[0744] The term "in vitro" refers to an event that takes places in a test system. In vitro assays encompass cell-based assays in which alive or dead cells may be are employed and may also encompass a cell-free assay in which no intact cells are employed.

[0745] The term "effective amount" or "therapeutically effective amount" refers to that amount of a compound or combination of compounds as described herein that is sufficient to effect the intended application including, but not limited to, disease treatment. A therapeutically effective amount may vary depending upon the intended application {in vitro or in vivo), or the subject and disease condition being treated {e.g., the weight, age and gender of the subject), the severity of the disease condition, or the manner of administration. The term also applies to a dose that will induce a particular response in target cells {e.g., the reduction of platelet adhesion and / or cell migration). The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether the compound is administered incombination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which the compound is carried.

[0746] A "therapeutic effect" as that term is used herein, encompasses a therapeutic benefit and / or a prophylactic benefit. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.

[0747] The terms "QD," "qd," or "q.d." mean quaque die, once a day, or once daily. The terms "BID," "bid," or "b.i.d." mean bis in die, twice a day, or twice daily. The terms "TID," "tid," or "t.i.d." mean ter in die, three times a day, or three times daily. The terms "QID," "qid," or "q.i.d." mean quater in die, four times a day, or four times daily.

[0748] The term "pharmaceutically acceptable salt" refers to salts derived from a variety of organic and inorganic counter ions known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Preferred inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. Preferred organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Specific examples include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts. The term "cocrystal" refers to a molecular complex derived from a number of cocrystal formers known in the art. Unlike a salt, a cocrystal typically does not involve hydrogen transfer between the cocrystal and the drug, and insteadinvolves intermolecular interactions, such as hydrogen bonding, aromatic ring stacking, or dispersive forces, between the cocrystal former and the drug in the crystal structure.

[0749] The terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and inert ingredients. The use of such pharmaceutically acceptable carriers or pharmaceutically acceptable excipients for active pharmaceutical ingredients is well known in the art. Except insofar as any conventional pharmaceutically acceptable carrier or pharmaceutically acceptable excipient is incompatible with the active pharmaceutical ingredient, its use in the therapeutic compositions of the invention is contemplated. Additional active pharmaceutical ingredients, such as other drugs, can also be incorporated into the described compositions, processes and methods.

[0750] The term "antigen" refers to a substance that induces an immune response. In some embodiments, an antigen is a molecule capable of being bound by an antibody or a T cell receptor (TCR) if presented by major histocompatibility complex (MHC) molecules. The term "antigen", as used herein, also encompasses T cell epitopes. An antigen is additionally capable of being recognized by the immune sytem. In some embodiments, an antigen is capable of inducing a humoral immune response or a cellular immune response leading to the activation of B lymphocytes and / or T lynphocytes. In some cases, this may require that the antigen contains or is linked to a Th cell epitope. An antigen can also have one or more epitopes (e.g., B- and T- epitopes). In some embodiments, an antigen will preferably react, typically in a highly specific and selective manner, with its corresponding antibody or TCR and not with the multitude of other antibodies or TCRs which may be induced by ther antigens.

[0751] The terms "antibody" and its plural form "antibodies" refer to wholeimmunoglobulins and any antigen-binding fragment ("antigen-binding portion") or single chains thereof. An "antibody" further refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, or an antigen-binding portion thereof. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHI, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region iscomprised of one domain, CL. The VH and VL regions of an antibody may be further subdivided into regions of hypervariability, which are referred to as complementarity determining regions (CDR) or hypervariable regions (HVR), and which can be interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen epitope or epitopes. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0752] The terms "monoclonal antibody," "mAb," "monoclonal antibody composition," or their plural forms refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Monoclonal antibodies specific to T FRSF receptors can be made using knowledge and skill in the art of injecting test subjects with suitable antigen and then isolating hybridomas expressing antibodies having the desired sequence or functional characteristics. DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.Recombinant production of antibodies will be described in more detail below.

[0753] The terms "antigen-binding portion" or "antigen-binding fragment" of an antibody (or simply "antibody portion" or "fragment"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linkedby a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a domain antibody (dAb) fragment (Ward, et al, Nature, 1989, 341, 544-546), which may consist of a VH or a VL domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules known as single chain Fv (scFv); see, e.g., Bird, et al, Science 1988, 242, 423-426; and Huston, et al, Proc. Natl. Acad. Sci. USA 1988, 85, 5879-5883). Such scFv antibodies are also intended to be encompassed within the terms "antigen-binding portion" or "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0754] The term "human antibody," as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). The term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0755] The term "human monoclonal antibody" refers to antibodies displaying a single binding specificity which have variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. In an embodiment, the human monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.

[0756] The term "recombinant human antibody", as used herein, includes all humanantibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (such as a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further below), (b) antibodies isolated from a host cell transformed to express the human antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial human antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.

[0757] As used herein, "isotype" refers to the antibody class (e.g., IgM or IgGl) that is encoded by the heavy chain constant region genes.

[0758] The phrases "an antibody recognizing an antigen" and "an antibody specific for an antigen" are used interchangeably herein with the term "an antibody which binds specifically to an antigen."

[0759] The term "human antibody derivatives" refers to any modified form of the human antibody, including a conjugate of the antibody and another active pharmaceutical ingredient or antibody. The terms "conjugate," "antibody-drug conjugate", "ADC," or "immunoconjugate" refers to an antibody, or a fragment thereof, conjugated to another therapeutic moiety, which can be conjugated to antibodies described herein using methods available in the art.

[0760] The terms "humanized antibody," "humanized antibodies," and "humanized" are intended to refer to antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. Additional framework region modifications may be made within the human framework sequences. Humanized forms of non-human (for example, murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For themost part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a 15 hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones, et al, Nature 1986, 321, 522-525; Riechmann, et al, Nature 1988, 332, 323-329; and Presta, Curr. Op. Struct. Biol 1992, 2, 593-596. The T FRSF agonists described herein may also be modified to employ any Fc variant which is known to impart an improvement (e.g., reduction) in effector function and / or FcR binding. The Fc variants may include, for example, any one of the amino acid substitutions disclosed in International Patent Application Publication Nos. WO 1988 / 07089 Al, WO1996 / 14339 Al, WO 1998 / 05787 Al, WO 1998 / 23289 Al, WO 1999 / 51642 Al, WO 99 / 58572 Al, WO 2000 / 09560 A2, WO 2000 / 32767 Al, WO 2000 / 42072 A2, WO 2002 / 44215 A2, WO 2002 / 060919 A2, WO 2003 / 074569 A2, WO 2004 / 016750 A2, WO 2004 / 029207 A2, WO 2004 / 035752 A2, WO 2004 / 063351 A2, WO 2004 / 074455 A2, WO 2004 / 099249 A2, WO 2005 / 040217 A2, WO 2005 / 070963 Al, WO 2005 / 077981 A2, WO 2005 / 092925 A2, WO 2005 / 123780 A2, WO 2006 / 019447 Al, WO 2006 / 047350 A2, and WO 2006 / 085967 A2; and U.S. Patent Nos. 5,648,260; 5,739,277; 5,834,250; 5,869,046; 6,096,871; 6,121,022; 6, 194,551; 6,242,195; 6,277,375; 6,528,624; 6,538, 124; 6,737,056; 6,821,505; 6,998,253; and 7,083,784; the disclosures of which are incorporated by reference herein.

[0761] The term "chimeric antibody" is intended to refer to antibodies in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody.

[0762] A "diabody" is a small antibody fragment with two antigen-binding sites. The fragments comprises a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL or VL-VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, e.g., European Patent No. EP 404,097, International PatentPublication No. WO 93 / 11161; and Bolliger, et al, Proc. Natl. Acad. Sci. USA 1993, 90, 6444- 6448.

[0763] The term "glycosylation" refers to a modified derivative of an antibody. An aglycoslated antibody lacks glycosylation. Glycosylation can be altered to, for example, increase the affinity of the antibody for antigen. Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Aglycosylation may increase the affinity of the antibody for antigen, as described in U.S. Patent Nos. 5,714,350 and 6,350,861. Additionally or alternatively, an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures. Such altered glycosylation patterns have been demonstrated to increase the ability of antibodies. Such carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies of the invention to thereby produce an antibody with altered glycosylation. For example, the cell lines Ms704, Ms705, and Ms709 lack the fucosyltransferase gene, FUT8 (alpha (1,6) fucosyltransferase), such that antibodies expressed in the Ms704, Ms705, and Ms709 cell lines lack fucose on their carbohydrates. The Ms704, Ms705, and Ms709 FUT8- / - cell lines were created by the targeted disruption of the FUT8 gene in CHO / DG44 cells using two replacement vectors (see e.g. U.S. Patent Publication No. 2004 / 0110704 or Yamane-Ohnuki, et al, Biotechnol. Bioeng., 2004, 87, 614-622). As another example, European Patent No. EP 1, 176,195 describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies expressed in such a cell line exhibit hypofucosylation byreducing or eliminating the alpha 1,6 bond-related enzyme, and also describes cell lines which have a low enzyme activity for adding fucose to the N-acetylglucosamine that binds to the Fc region of the antibody or does not have the enzyme activity, for example the rat myeloma cell line YB2 / 0 (ATCC CRL 1662). International Patent Publication WO 03 / 035835 describes a variant CHO cell line, Lec 13 cells, with reduced ability to attach fucose to Asn(297)-linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in that host cell (see also Shields, et al, J. Biol Chem. 2002, 277, 26733-26740. International Patent Publication WO 99 / 54342 describes cell lines engineered to express glycoprotein-modifying glycosyl transferases (e.g., beta(l,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures which results in increased ADCC activity of the antibodies (see also Umana, et al, Nat. Biotech. 1999, 77, 176-180).Alternatively, the fucose residues of the antibody may be cleaved off using a fucosidase enzyme. For example, the fucosidase alpha-L-fucosidase removes fucosyl residues from antibodies as described in Tarentino, et al., Biochem. 1975, 14, 5516-5523.

[0764] "Pegylation" refers to a modified antibody or fusion protein, or a fragment thereof, that typically is reacted with polyethylene glycol (PEG), such as a reactive ester or aldehyde derivative of PEG, under conditions in which one or more PEG groups become attached to the antibody or antibody fragment. Pegylation may, for example, increase the biological (e.g., serum) half life of the antibody. Preferably, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive water- soluble polymer). As used herein, the term "polyethylene glycol" is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (Ci-Cio) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. The protein or antibody to be pegylated may be an aglycosylated protein or antibody. Methods for pegylation are known in the art and can be applied to the antibodies of the invention, as described for example in European Patent Nos. EP 0154316 and EP 0401384 and U.S. Patent No. 5,824,778, the disclosures of each of which are incorporated by reference herein.

[0765] The terms "fusion protein" or "fusion polypeptide" refer to proteins that combine the properties of two or more individual proteins. Such proteins have at least two heterologous polypeptides covalently linked either directly or via an amino acid linker. The polypeptides forming the fusion protein are typically linked C-terminus to N-terminus, although they can alsobe linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. The polypeptides of the fusion protein can be in any order and may include more than one of either or both of the constituent polypeptides. The term encompasses conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, interspecies homologs, and immunogenic fragments of the antigens that make up the fusion protein. Fusion proteins of the disclosure can also comprise additional copies of a component antigen or immunogenic fragment thereof. The fusion protein may contain one or more binding domains linked together and further linked to an Fc domain, such as an IgG Fc domain. Fusion proteins may be further linked together to mimic a monoclonal antibody and provide six or more binding domains. Fusion proteins may be produced by recombinant methods as is known in the art. Preparation of fusion proteins are known in the art and are described, e.g., in International Patent ApplicationPublication Nos. WO 1995 / 027735 Al, WO 2005 / 103077 Al, WO 2008 / 025516 Al, WO 2009 / 007120 Al, WO 2010 / 003766 Al, WO 2010 / 010051 Al, WO 2010 / 078966 Al, U.S. Patent Application Publication Nos. US 2015 / 0125419 Al and US 2016 / 0272695 Al, and U.S. Patent No. 8,921,519, the disclosures of each of which are incorporated by reference herein.

[0766] The term "heterologous" when used with reference to portions of a nucleic acid or protein indicates that the nucleic acid or protein comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source, or coding regions from different sources. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

[0767] The term "conservative amino acid substitutions" means amino acid sequence modifications which do not abrogate the binding of an antibody or fusion protein to the antigen. Conservative amino acid substitutions include the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. Six general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gin, Glu); Class IV(His, Arg, Lys); Class V (He, Leu, Val, Met); and Class VI (Phe, Tyr, Tip). For example, substitution of an Asp for another class III residue such as Asn, Gin, or Glu, is a conservative substitution. Thus, a predicted nonessential amino acid residue in an antibody is preferably replaced with another amino acid residue from the same class. Methods of identifying amino acid conservative substitutions which do not eliminate antigen binding are well-known in the art (see, e.g., Brummell, et al., Biochemistry 1993, 32, 1180-1187; Kobayashi, et al, Protein Eng. 1999, 12, 879-884 (1999); and Burks, et al, Proc. Natl. Acad. Sci. USA 1997, 94, 412-417.

[0768] The terms "sequence identity," "percent identity," and "sequence percent identity" (or synonyms thereof, e.g., "99% identical") in the context of two or more nucleic acids or polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity. The percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences. Suitable programs to determine percent sequence identity include for example the BLAST suite of programs available from the U.S. Government's National Center for Biotechnology Information BLAST web site. Comparisons between two sequences can be carried using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or MegAlign, available from DNASTAR, are additional publicly available software programs that can be used to align sequences. One skilled in the art can determine appropriate parameters for maximal alignment by particular alignment software. In certain embodiments, the default parameters of the alignment software are used.

[0769] Certain embodiments of the present invention comprise a variant of an antibody or fusion protein. As used herein, the term "variant" encompasses but is not limited to antibodies or fusion proteins which comprise an amino acid sequence which differs from the amino acid sequence of a reference antibody by way of one or more substitutions, deletions and / or additions at certain positions within or adjacent to the amino acid sequence of the reference antibody. The variant may comprise one or more conservative substitutions in its amino acid sequence as compared to the amino acid sequence of a reference antibody. Conservative substitutions mayinvolve, e.g., the substitution of similarly charged or uncharged amino acids. The variant retains the ability to specifically bind to the antigen of the reference antibody.

[0770] Nucleic acid sequences implicitly encompass conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues. Batzer, et al, Nucleic Acid Res. 1991, 19, 5081; Ohtsuka, et al, J. Biol. Chem. 1985, 260, 2605-2608; Rossolini, et al., Mol. Cell. Probes 1994, 8, 91-98. The term nucleic acid is used interchangeably with cDNA, mRNA, oligonucleotide, and polynucleotide.

[0771] The term "biosimilar" means a biological product, including a monoclonal antibody or fusion protein, that is highly similar to a U.S. licensed reference biological productnotwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. Furthermore, a similar biological or "biosimilar" medicine is a biological medicine that is similar to another biological medicine that has already been authorized for use by the European Medicines Agency. The term "biosimilar" is also used synonymously by other national and regional regulatory agencies. Biological products or biological medicines are medicines that are made by or derived from a biological source, such as a bacterium or yeast. They can consist of relatively small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. For example, if the reference monoclonal antibody is rituximab, an biosimilar monoclonal antibody approved by drug regulatory authorities with reference to rituximab is a "biosimilar to" rituximab or is a "biosimilar thereof of rituximab. In Europe, a similar biological or"biosimilar" medicine is a biological medicine that is similar to another biological medicine that has already been authorized for use by the European Medicines Agency (EMA). The relevant legal basis for similar biological applications in Europe is Article 6 of Regulation (EC) No 726 / 2004 and Article 10(4) of Directive 2001 / 83 / EC, as amended and therefore in Europe, the biosimilar may be authorised, approved for authorisation or subject of an application for authorisation under Article 6 of Regulation (EC) No 726 / 2004 and Article 10(4) of Directive 2001 / 83 / EC. The already authorized original biological medicinal product may be referred to asa "reference medicinal product" in Europe. Some of the requirements for a product to be considered a biosimilar are outlined in the CHMP Guideline on Similar Biological Medicinal Products. In addition, product specific guidelines, including guidelines relating to monoclonal antibody biosimilars, are provided on a product-by-product basis by the EMA and published on its website. A biosimilar as described herein may be similar to the reference medicinal product by way of quality characteristics, biological activity, mechanism of action, safety profiles and / or efficacy. In addition, the biosimilar may be used or be intended for use to treat the same conditions as the reference medicinal product. Thus, a biosimilar as described herein may be deemed to have similar or highly similar quality characteristics to a reference medicinal product. Alternatively, or in addition, a biosimilar as described herein may be deemed to have similar or highly similar biological activity to a reference medicinal product. Alternatively, or in addition, a biosimilar as described herein may be deemed to have a similar or highly similar safety profile to a reference medicinal product. Alternatively, or in addition, a biosimilar as described herein may be deemed to have similar or highly similar efficacy to a reference medicinal product. As described herein, a biosimilar in Europe is compared to a reference medicinal product which has been authorised by the EMA. However, in some instances, the biosimilar may be compared to a biological medicinal product which has been authorised outside the European Economic Area (a non-EEA authorised "comparator") in certain studies. Such studies include for example certain clinical and in vivo non-clinical studies. As used herein, the term "biosimilar" also relates to a biological medicinal product which has been or may be compared to a non-EEA authorised comparator. Certain biosimilars are proteins such as antibodies, antibody fragments (for example, antigen binding portions) and fusion proteins. A protein biosimilar may have an amino acid sequence that has minor modifications in the amino acid structure (including for example deletions, additions, and / or substitutions of amino acids) which do not significantly affect the function of the polypeptide. The biosimilar may comprise an amino acid sequence having a sequence identity of 97% or greater to the amino acid sequence of its reference medicinal product, e.g., 97%, 98%, 99% or 100%. The biosimilar may comprise one or more post- translational modifications, for example, although not limited to, glycosylation, oxidation, deamidation, and / or truncation which is / are different to the post-translational modifications of the reference medicinal product, provided that the differences do not result in a change in safety and / or efficacy of the medicinal product. The biosimilar may have an identical or differentglycosylation pattern to the reference medicinal product. Particularly, although not exclusively, the biosimilar may have a different glycosylation pattern if the differences address or are intended to address safety concerns associated with the reference medicinal product.Additionally, the biosimilar may deviate from the reference medicinal product in for example its strength, pharmaceutical form, formulation, excipients and / or presentation, providing safety and efficacy of the medicinal product is not compromised. In some embodiments, a biosimilar is provided as a composition which further comprises one or more excipients, wherein the one or more excipients are the same or different to the excipients comprised in a reference medicinal product or reference biological product. The biosimilar may comprise differences in for example pharmacokinetic (PK) and / or pharmacodynamic (PD) profiles as compared to the reference medicinal product but is still deemed sufficiently similar to the reference medicinal product as to be authorised or considered suitable for authorisation. In certain circumstances, the biosimilar exhibits different binding characteristics as compared to the reference medicinal product, wherein the different binding characteristics are considered by a Regulatory Authority such as the EMA not to be a barrier for authorisation as a similar biological product. The term"biosimilar" is also used synonymously by other national and regional regulatory agencies.

[0772] As used herein, the term "4-1BB agonist" may refer to any antibody or protein that specifically binds to 4-1BB (CD137) antigen. By "specifically binds" it is meant that the binding molecules exhibit essentially background binding to non-4- IBB molecules. The 4- IBB agonist may be any 4-1BB agonist known in the art. In particular, it is one of the 4-1BB agonists described in more detail herein. An isolated binding molecule that specifically binds 4-1BB may, however, have cross-reactivity to 4- IBB molecules from other species. 4- IBB agonistic antibodies and proteins may also specifically bind to e.g., human 4-1BB (h4-lBB or hCD137) on T cells.

[0773] As used herein, the term "OX40 agonist" may refer to any antibody or protein that specifically binds to OX40 (CD 134) antigen. By "specifically binds" it is meant that the binding molecules exhibit essentially background binding to non-OX40 molecules. The OX40 agonist may be any OX40 agonist known in the art. In particular, it is one of the OX40 agonists described in more detail herein. An isolated binding molecule that specifically binds OX40 may, however, have cross-reactivity to OX40 molecules from other species. OX40 agonistic antibodies and proteins may also specifically bind to e.g., human OX40 (hOX40 or hCD134) onT cells.

[0774] As used herein, the term "CD27 agonist" may refer to any antibody or protein that specifically binds to CD27 antigen. By "specifically binds" it is meant that the binding molecules exhibit essentially background binding to non-CD27 molecules. The CD27 agonist may be any CD27 agonist known in the art. In particular, it is one of the CD27 agonists described in more detail herein. An isolated binding molecule that specifically binds CD27 may, however, have cross-reactivity to CD27 molecules from other species. CD27 agonistic antibodies and proteins may also specifically bind to e.g., human CD27 (hCD27) on T cells.

[0775] As used herein, the term "GITR agonist" includes molecules that contain at least one antigen binding site that specifically binds to GITR (CD357). By "specifically binds" it is meant that the binding molecules exhibit essentially background binding to non-GITR molecules. The GITR agonist may be any GITR agonist known in the art. In particular, it is one of the GITR agonists described in more detail herein. An isolated binding molecule that specifically binds GITR may, however, have cross-reactivity to GITR molecules from other species. GITR agonistic antibodies and proteins may also specifically bind to e.g., human GITR (hGITR) on T cells and dendritic cells.

[0776] As used herein, the term "HVEM agonist" includes molecules that contain at least one antigen binding site that specifically binds to HVEM (CD270). By "specifically binds" it is meant that the binding molecules exhibit essentially background binding to non-HVEM molecules. The HVEM agonist may be any HVEM agonist known in the art. In particular, it is one of the HVEM agonists described in more detail herein. An isolated binding molecule that specifically binds HVEM may, however, have cross-reactivity to HVEM molecules from other species. HVEM agonistic antibodies and proteins may also specifically bind to e.g., human HVEM (hHVEM) on T cells.

[0777] The term "hematological malignancy" refers to mammalian cancers and tumors of the hematopoietic and lymphoid tissues, including but not limited to tissues of the blood, bone marrow, lymph nodes, and lymphatic system. Hematological malignancies are also referred to as "liquid tumors." Hematological malignancies include, but are not limited to, acutelymphoblastic leukemia (ALL), chronic lymphocytic lymphoma (CLL), small lymphocytic lymphoma (SLL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML),acute monocytic leukemia (AMoL), Hodgkin's lymphoma, and non-Hodgkin's lymphomas. The term "B cell hematological malignancy" refers to hematological malignancies that affect B cells.

[0778] The term "solid tumor" refers to an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant. The term "solid tumor cancer" refers to malignant, neoplastic, or cancerous solid tumors. Solid tumor cancers include, but are not limited to, sarcomas, carcinomas, and lymphomas, such as cancers of the lung, breast, prostate, colon, rectum, and bladder. The tissue structure of solid tumors includesinterdependent tissue compartments including the parenchyma (cancer cells) and the supporting stromal cells in which the cancer cells are dispersed and which may provide a supporting microenvironment.

[0779] The term "microenvironment," as used herein, may refer to the solid or hematological tumor microenvironment as a whole or to an individual subset of cells within themicroenvironment. The tumor microenvironment, as used herein, refers to a complex mixture of "cells, soluble factors, signaling molecules, extracellular matrices, and mechanical cues that promote neoplastic transformation, support tumor growth and invasion, protect the tumor from host immunity, foster therapeutic resistance, and provide niches for dominant metastases to thrive," as described in Swartz, et al., Cancer Res., 2012, 72, 2473. Although tumors express antigens that should be recognized by T cells, tumor clearance by the immune system is rare because of immune suppression by the microenvironment.

[0780] For the avoidance of doubt, it is intended herein that particular features (for example integers, characteristics, values, uses, diseases, formulae, compounds or groups) described in conjunction with a particular aspect, embodiment or example of the invention are to be understood as applicable to any other aspect, embodiment or example described herein unless incompatible therewith. Thus such features may be used where appropriate in conjunction with any of the definition, claims or embodiments defined herein. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined in any combination, exceptcombinations where at least some of the features and / or steps are mutually exclusive. The invention is not restricted to any details of any disclosed embodiments. The invention extends to any novel one, or novel combination, of the features disclosed in this specification (including anyaccompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

[0781] The terms "about" and "approximately" mean within a statistically meaningful range of a value. Such a range can be within an order of magnitude, preferably within 50%, more preferably within 20%, more preferably still within 10%, and even more preferably within 5% of a given value or range. The allowable variation encompassed by the terms "about" or"approximately" depends on the particular system under study, and can be readily appreciated by one of ordinary skill in the art. Moreover, as used herein, the terms "about" and "approximately" mean that dimensions, sizes, formulations, parameters, shapes and other quantities and characteristics are not and need not be exact, but may be approximate and / or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art. In general, a dimension, size, formulation, parameter, shape or other quantity or characteristic is "about" or "approximate" whether or not expressly stated to be such. It is noted that embodiments of very different sizes, shapes and dimensions may employ the described arrangements.

[0782] The transitional terms "comprising," "consisting essentially of," and "consisting of," when used in the appended claims, in original and amended form, define the claim scope with respect to what unrecited additional claim elements or steps, if any, are excluded from the scope of the claim(s). The term "comprising" is intended to be inclusive or open-ended and does not exclude any additional, unrecited element, method, step or material. The term "consisting of excludes any element, step or material other than those specified in the claim and, in the latter instance, impurities ordinary associated with the specified material(s). The term "consisting essentially of limits the scope of a claim to the specified elements, steps or material(s) and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. All compositions, methods, and kits described herein that embody the present invention can, in alternate embodiments, be more specifically defined by any of the transitional terms"comprising," "consisting essentially of," and "consisting of."4-1BB (CD 137) Agonists

[0783] In an embodiment, the T FRSF agonist is a 4-1BB (CD137) agonist. The 4-1BB agonist may be any 4-1BB binding molecule known in the art. The 4-1BB binding moleculemay be a monoclonal antibody or fusion protein capable of binding to human or mammalian 4- 1BB. The 4-1BB agonists or 4-1BB binding molecules may comprise an immunoglobulin heavy chain of any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule. The 4-1BB agonist or 4-1BB binding molecule may have both a heavy and a light chain. As used herein, the term binding molecule also includes antibodies (including full length antibodies), monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), human, humanized or chimeric antibodies, and antibody fragments, e.g., Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, epitope- binding fragments of any of the above, and engineered forms of antibodies, e.g., scFv molecules, that bind to 4-1BB. In an embodiment, the 4-1BB agonist is an antigen binding protein that is a fully human antibody. In an embodiment, the 4- IBB agonist is an antigen binding protein that is a humanized antibody. In some embodiments, 4- IBB agonists for use in the presently disclosed methods and compositions include anti-4-lBB antibodies, human anti-4-lBB antibodies, mouse anti-4-lBB antibodies, mammalian anti-4-lBB antibodies, monoclonal anti-4-lBB antibodies, polyclonal anti-4-lBB antibodies, chimeric anti-4-lBB antibodies, anti-4-lBB adnectins, anti-4- 1BB domain antibodies, single chain anti-4-lBB fragments, heavy chain anti-4-lBB fragments, light chain anti-4-lBB fragments, anti-4-lBB fusion proteins, and fragments, derivatives, conjugates, variants, or biosimilars thereof. Agonistic anti-4-lBB antibodies are known to induce strong immune responses. Lee, et al, PLOS One 2013, 8, e69677. In a preferred embodiment, the 4-1BB agonist is an agonistic, anti-4-lBB humanized or fully human monoclonal antibody (i.e., an antibody derived from a single cell line). In an embodiment, the 4- 1BB agonist is EU-101 (Eutilex Co. Ltd.), utomilumab, or urelumab, or a fragment, derivative, conjugate, variant, or biosimilar thereof. In a preferred embodiment, the 4- IBB agonist is utomilumab or urelumab, or a fragment, derivative, conjugate, variant, or biosimilar thereof.

[0784] In a preferred embodiment, the 4- IBB agonist or 4- IBB binding molecule may also be a fusion protein. In a preferred embodiment, a multimeric 4- IBB agonist, such as a trimeric or hexameric 4-1BB agonist (with three or six ligand binding domains), may induce superior receptor (4-1BBL) clustering and internal cellular signaling complex formation compared to an agonistic monoclonal antibody, which typically possesses two ligand binding domains. Trimeric (trivalent) or hexameric (or hexavalent) or greater fusion proteins comprising three TNFRSFbinding domains and IgGl-Fc and optionally further linking two or more of these fusion proteins are described, e.g., in Gieffers, et al., Mol. Cancer Therapeutics 2013, 12, 2735-47.

[0785] Agonistic 4- IBB antibodies and fusion proteins are known to induce strong immune responses. In a preferred embodiment, the 4-1BB agonist is a monoclonal antibody or fusion protein that binds specifically to 4- IBB antigen in a manner sufficient to reduce toxicity. In some embodiments, the 4-1BB agonist is an agonistic 4-1BB monoclonal antibody or fusion protein that abrogates antibody-dependent cellular toxicity (ADCC), for example NK cell cytotoxicity. In some embodiments, the 4-1BB agonist is an agonistic 4-1BB monoclonal antibody or fusion protein that abrogates antibody-dependent cell phagocytosis (ADCP). In some embodiments, the 4-1BB agonist is an agonistic 4-1BB monoclonal antibody or fusion protein that abrogates complement-dependent cytotoxicity (CDC). In some embodiments, the 4- 1BB agonist is an agonistic 4-1BB monoclonal antibody or fusion protein which abrogates Fc region functionality.

[0786] In some embodiments, the 4- IBB agonists are characterized by binding to human 4- 1BB (SEQ ID NO:9) with high affinity and agonistic activity. In an embodiment, the 4-1BB agonist is a binding molecule that binds to human 4-1BB (SEQ ID NO:9). In an embodiment, the 4-1BB agonist is a binding molecule that binds to murine 4-1BB (SEQ ID NO: 10). The amino acid sequences of 4- IBB antigen to which a 4- IBB agonist or binding molecule binds are summarized in Table 3.TABLE 3. Amino acid sequences of 4-1BB antig

[0787] In some embodiments, the compositions, processes and methods described include a 4- IBB agonist that binds human or murine 4- IBB with a KD of about 100 pM or lower, bindshuman or murine 4- IBB with a KD of about 90 pM or lower, binds human or murine 4- IBB with a KD of about 80 pM or lower, binds human or murine 4- IBB with a KD of about 70 pM or lower, binds human or murine 4-lBB with a KD of about 60 pM or lower, binds human or murine 4- IBB with a KD of about 50 pM or lower, binds human or murine 4- IBB with a KD of about 40 pM or lower, or binds human or murine 4-lBB with a KD of about 30 pM or lower.

[0788] In some embodiments, the compositions, processes and methods described include a 4-lBB agonist that binds to human or murine 4-lBB with a kassoc of about 7.5 x 1051 / M s or faster, binds to human or murine 4-lBB with a kassoc of about 7.5 x 1051 / M s or faster, binds to human or murine 4-lBB with a kassoc of about 8χ10^ 1 / M s or faster, binds to human or murine 4-lBB with a kassoc of about 8.5 x 1051 / M s or faster, binds to human or murine 4-lBB with a kassoc of about 9 x 1051 / M s or faster, binds to human or murine 4- IBB with a kassoc of about 9.5 x 1051 / M s or faster, or binds to human or murine 4-lBB with a kassoc of about 1 x 1061 / M s or faster.

[0789] In some embodiments, the compositions, processes and methods described include a 4-lBB agonist that binds to human or murine 4-lBB with a kdissoc of about 2 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.1 x 10"51 / s or slower , binds to human or murine 4-lBB with a kdissoc of about 2.2 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.3 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.4 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.5 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.6 x 10"51 / s or slower or binds to human or murine 4- IBB with a kdissoc of about 2.7 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.8 x 10"51 / s or slower, binds to human or murine 4-lBB with a kdissoc of about 2.9 x 10"51 / s or slower, or binds to human or murine 4-lBB with a kdissoc of about 3 x 10"51 / s or slower.

[0790] In some embodiments, the compositions, processes and methods described include a 4- IBB agonist that binds to human or murine 4- IBB with an ICso of about 10 nM or lower, binds to human or murine 4- IBB with an ICso of about 9 nM or lower, binds to human or murine 4- 1BB with an ICso of about 8 nM or lower, binds to human or murine 4- IBB with an ICso of about 7 nM or lower, binds to human or murine 4-lBB with an ICso of about 6 nM or lower, binds to human or murine 4-lBB with an ICso of about 5 nM or lower, binds to human or murine 4-lBBwith an IC50 of about 4 nM or lower, binds to human or murine 4- IBB with an IC50 of about 3 nM or lower, binds to human or murine 4- IBB with an IC50 of about 2 nM or lower, or binds to human or murine 4- IBB with an IC50 of about 1 nM or lower.

[0791] In a preferred embodiment, the 4- IBB agonist is utomilumab, also known as PF- 05082566 or MOR-7480, or a fragment, derivative, variant, or biosimilar thereof. Utomilumab is available from Pfizer, Inc. Utomilumab is an immunoglobulin G2-lambda, anti-[Homo sapiens TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], Homo sapiens (fully human) monoclonal antibody. The amino acid sequences of utomilumab are set forth in Table 4. Utomilumab comprises glycosylation sites at Asn59 and Asn292; heavy chain intrachain disulfide bridges at positions 22-96 (VH-VL), 143- 199 (CH1-CL), 256-316 (CH2) and 362-420 (CH3); light chain intrachain disulfide bridges at positions 22'-87' (VH-VL) and 136'-195' (CH1-CL); interchain heavy chain-heavy chain disulfide bridges at IgG2A isoform positions 218-218, 219-219, 222-222, and 225-225, at IgG2A / B isoform positions 218-130, 219-219, 222-222, and 225-225, and at IgG2B isoform positions 219- 130 (2), 222-222, and 225-225; and interchain heavy chain-light chain disulfide bridges at IgG2A isoform positions 130-213' (2), IgG2A / B isoform positions 218-213' and 130-213', and at IgG2B isoform positions 218-213' (2). The preparation and properties of utomilumab and its variants and fragments are described in U.S. Patent Nos. 8,821,867; 8,337,850; and 9,468,678, and International Patent Application Publication No. WO 2012 / 032433 Al, the disclosures of each of which are incorporated by reference herein. Preclinical characteristics of utomilumab are described in Fisher, et al., Cancer Immunolog. & Immunother. 2012, 61, 1721-33. Current clinical trials of utomilumab in a variety of hematological and solid tumor indications include U.S. National Institutes of Health clinicaltrials.gov identifiers NCT02444793, NCT01307267, NCT02315066, and NCT02554812.

[0792] In an embodiment, a 4- IBB agonist comprises a heavy chain given by SEQ ID NO: 11 and a light chain given by SEQ ID NO: 12. In an embodiment, a 4-1BB agonist comprises heavy and light chains having the sequences shown in SEQ ID NO: 11 and SEQ ID NO: 12,respectively, or antigen binding fragments, Fab fragments, single-chain variable fragments (scFv), variants, or conjugates thereof. In an embodiment, a 4- IBB agonist comprises heavy and light chains that are each at least 99% identical to the sequences shown in SEQ ID NO: 11 and SEQ ID NO: 12, respectively. In an embodiment, a 4-1BB agonist comprises heavy and lightchains that are each at least 98% identical to the sequences shown in SEQ ID NO: 11 and SEQ ID NO: 12, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 97% identical to the sequences shown in SEQ ID NO: 11 and SEQ ID NO: 12, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 96% identical to the sequences shown in SEQ ID NO: 11 and SEQ ID NO: 12, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 95% identical to the sequences shown in SEQ ID NO: 11 and SEQ ID NO: 12, respectively.

[0793] In an embodiment, the 4- IBB agonist comprises the heavy and light chain CDRs or variable regions (VRs) of utomilumab. In an embodiment, the 4- IBB agonist heavy chain variable region (VH) comprises the sequence shown in SEQ ID NO: 13, and the 4-lBB agonist light chain variable region (VL) comprises the sequence shown in SEQ ID NO: 14, and conservative amino acid substitutions thereof. In an embodiment, a 4- IBB agonist comprises VH and VL regions that are each at least 99% identical to the sequences shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In an embodiment, a 4-lBB agonist comprises VH and VL regions that are each at least 98% identical to the sequences shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In an embodiment, a 4-lBB agonist comprises VH and VL regions that are each at least 97% identical to the sequences shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In an embodiment, a 4- IBB agonist comprises VH and VL regions that are each at least 96%) identical to the sequences shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In an embodiment, a 4- IBB agonist comprises VH and VL regions that are each at least 95% identical to the sequences shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In an embodiment, a 4-lBB agonist comprises an scFv antibody comprising VH and VL regions that are each at least 99% identical to the sequences shown in SEQ ID NO: 13 and SEQ ID NO: 14.

[0794] In an embodiment, a 4- IBB agonist comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and conservative amino acid substitutions thereof, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO:20, respectively, and conservative amino acid substitutions thereof.

[0795] In an embodiment, the 4-lBB agonist is a 4-lBB agonist biosimilar monoclonalantibody approved by drug regulatory authorities with reference to utomilumab. In an embodiment, the biosimilar monoclonal antibody comprises an 4- IBB antibody comprising an amino acid sequence which has at least 97% sequence identity, e.g., 97%, 98%, 99% or 100% sequence identity, to the amino acid sequence of a reference medicinal product or reference biological product and which comprises one or more post-translational modifications as compared to the reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is utomilumab. In someembodiments, the one or more post-translational modifications are selected from one or more of: glycosylation, oxidation, deamidation, and truncation. In some embodiments, the biosimilar is a 4- IBB agonist antibody authorized or submitted for authorization, wherein the 4- IBB agonist antibody is provided in a formulation which differs from the formulations of a reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is utomilumab. The 4-lBB agonist antibody may be authorized by a drug regulatory authority such as the U.S. FDA and / or the European Union's EMA. In some embodiments, the biosimilar is provided as a composition which further comprises one or more excipients, wherein the one or more excipients are the same or different to the excipients comprised in a reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is utomilumab. In someembodiments, the biosimilar is provided as a composition which further comprises one or more excipients, wherein the one or more excipients are the same or different to the excipients comprised in a reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is utomilumab.TABLE 4. Amino acid sequences for 4-lBB agonist antibodies related to utomilumab.Identifier Sequence (One-Letter Amino Acid Symbols)SEQ ID NO: 11 EVQLVQSGAE VKKPGESLRI SCKGSGYSFS TYWISWVRQM PGKGLEWMGK IYPGDSYTNY 60 heavy chain for SPSFQGQVTI SADKSISTAY LQWSSLKASD TAMYYCARGY GIFDYWGQGT LVTVSSASTK 120 utomilumab GPSVFPLAPC SRSTSESTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS 180LSSWTVPSS NFGTQTYTCN VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP 240 KPKDTLMISR TPEVTCVWD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRWSV 300 LTWHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE PQVYTLPPSR EEMTKNQVSL 360 TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF LYSKLTVDKS RWQQGNVFSC 420 SVMHEALHNH YTQKSLSLSP G 441SEQ ID NO: 12 SYELTQPPSV SVSPGQTASI TCSGDNIGDQ YAHWYQQKPG QSPVLVIYQD KNRPSGIPER 60 light chain for FSGSNSGNTA TLTISGTQAM DEADYYCATY TGFGSLAVFG GGTKLTVLGQ PKAAPSVTLF 120 utomilumab PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL 180SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS 214SEQ ID NO: 13 EVQLVQSGAE VKKPGESLRI SCKGSGYSFS TYWISWVRQM PGKGLEWMG KIYPGDSYTN 60 heavy chain YSPSFQGQVT ISADKSISTA YLQWSSLKAS DTAMYYCARG YGIFDYWGQ GTLVTVSS 118variable regionfor utomilumabSEQ ID NO: 14 SYELTQPPSV SVSPGQTASI TCSGDNIGDQ YAHWYQQKPG QSPVLVIYQD KNRPSGIPER 60 light chain FSGSNSGNTA TLTISGTQAM DEADYYCATY TGFGSLAVFG GGTKLTVL 108 variable regionfor utomilumabSEQ ID NO: 15 STYWIS 6 heavy chain CDR1for utomilumabSEQ ID NO: 16 KIYPGDSYTN YSPSFQG 17 heavy chain CDR2for utomilumabSEQ ID NO: 17 RGYGIFDY 8 heavy chain CDR3for utomilumabSEQ ID NO: 18 SGDNIGDQYA H 11 light chain CDR1for utomilumabSEQ ID NO: 19 QDKNRPS 7 light chain CDR2for utomilumabSEQ ID NO:20 ATYTGFGSLA V 11 light chain CDR3for utomilumab

[0796] In a preferred embodiment, the 4- IBB agonist is the monoclonal antibody urelumab, also known as BMS-663513 and 20H4.9.h4a, or a fragment, derivative, variant, or biosimilar thereof. Urelumab is available from Bristol-Myers Squibb, Inc., and Creative Biolabs, Inc. Urelumab is an immunoglobulin G4-kappa, anti-[Homo sapiens TNFRSF9 (tumor necrosis factor receptor superfamily member 9, 4-lBB, T cell antigen ILA, CD137)], Homo sapiens (fully human) monoclonal antibody. The amino acid sequences of urelumab are set forth in Table 5. Urelumab comprises N-glycosylation sites at positions 298 (and 298"); heavy chain intrachain disulfide bridges at positions 22-95 (VH-VL), 148-204 (CH1-CL), 262-322 (CH2) and 368-426 (CH3) (and at positions 22"-95", 148"-204", 262"-322", and 368"-426"); light chain intrachain disulfide bridges at positions 23'-88' (VH-VL) and 136'-196' (CH1-CL) (and at positions 23"'-88" ' and 136" '-196" '); interchain heavy chain-heavy chain disulfide bridges at positions 227-227" and 230-230"; and interchain heavy chain-light chain disulfide bridges at 135-216' and 135 " -216" ' . The preparation and properties of urelumab and its variants and fragments are described in U.S. Patent Nos. 7,288,638 and 8,962,804, the disclosures of which are incorporated by reference herein. The preclinical and clinical characteristics of urelumab are described in Segal, et al., Clin. Cancer Res. 2016, available at http: / dx. doi.org / 10.1158 / 1078- 0432.CCR-16-1272. Current clinical trials of urelumab in a variety of hematological and solid tumor indications include U.S. National Institutes of Health clinicaltrials.gov identifiersNCT01775631, NCT02110082, NCT02253992, and NCT01471210.

[0797] In an embodiment, a 4- IBB agonist comprises a heavy chain given by SEQ ID NO:21and a light chain given by SEQ ID NO:22. In an embodiment, a 4-lBB agonist comprises heavy and light chains having the sequences shown in SEQ ID NO:21 and SEQ ID NO:22,respectively, or antigen binding fragments, Fab fragments, single-chain variable fragments (scFv), variants, or conjugates thereof. In an embodiment, a 4- IBB agonist comprises heavy and light chains that are each at least 99% identical to the sequences shown in SEQ ID NO:21 and SEQ ID NO:22, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 98% identical to the sequences shown in SEQ ID NO:21 and SEQ ID NO:22, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 97% identical to the sequences shown in SEQ ID NO:21 and SEQ ID NO:22, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 96% identical to the sequences shown in SEQ ID NO:21 and SEQ ID NO:22, respectively. In an embodiment, a 4-lBB agonist comprises heavy and light chains that are each at least 95% identical to the sequences shown in SEQ ID NO:21 and SEQ ID NO:22, respectively.

[0798] In an embodiment, the 4- IBB agonist comprises the heavy and light chain CDRs or variable regions (VRs) of urelumab. In an embodiment, the 4-lBB agonist heavy chain variable region (VH) comprises the sequence shown in SEQ ID NO:23, and the 4-lBB agonist light chain variable region (VL) comprises the sequence shown in SEQ ID NO:24, and conservative amino acid substitutions thereof. In an embodiment, a 4- IBB agonist comprises VH and VL regions that are each at least 99% identical to the sequences shown in SEQ ID NO:23 and SEQ ID NO:24, respectively. In an embodiment, a 4- IBB agonist comprises VH and VL regions that are each at least 98% identical to the sequences shown in SEQ ID NO:23 and SEQ ID NO:24, respectively. In an embodiment, a 4- IBB agonist comprises VH and VL regions that are each at least 97% identical to the sequences shown in SEQ ID NO:23 and SEQ ID NO:24, respectively. In an embodiment, a 4-lBB agonist comprises VH and VL regions that are each at least 96% identical to the sequences shown in SEQ ID NO:23 and SEQ ID NO:24, respectively. In an embodiment, a 4-lBB agonist comprises VH and VL regions that are each at least 95% identical to the sequences shown in SEQ ID NO:23 and SEQ ID NO:24, respectively. In an embodiment, a 4- 1BB agonist comprises an scFv antibody comprising VH and VL regions that are each at least 99% identical to the sequences shown in SEQ ID NO:23 and SEQ ID NO:24.

[0799] In an embodiment, a 4- IBB agonist comprises heavy chain CDR1, CDR2 and CDR3domains having the sequences set forth in SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, respectively, and conservative amino acid substitutions thereof, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, respectively, and conservative amino acid substitutions thereof.

[0800] In an embodiment, the 4-1BB agonist is a 4-1BB agonist biosimilar monoclonal antibody approved by drug regulatory authorities with reference to urelumab. In an embodiment, the biosimilar monoclonal antibody comprises an 4-1BB antibody comprising an amino acid sequence which has at least 97% sequence identity, e.g., 97%, 98%, 99% or 100% sequence identity, to the amino acid sequence of a reference medicinal product or reference biological product and which comprises one or more post-translational modifications as compared to the reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is urelumab. In some embodiments, the one or more post-translational modifications are selected from one or more of: glycosylation, oxidation, deamidation, and truncation. In some embodiments, the biosimilar is a 4- IBB agonist antibody authorized or submitted for authorization, wherein the 4- IBB agonist antibody is provided in a formulation which differs from the formulations of a reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is urelumab. The 4-1BB agonist antibody may be authorized by a drug regulatory authority such as the U.S. FDA and / or the European Union's EMA. In some embodiments, the biosimilar is provided as a composition which further comprises one or more excipients, wherein the one or more excipients are the same or different to the excipients comprised in a reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is urelumab. In some embodiments, the biosimilar is provided as acomposition which further comprises one or more excipients, wherein the one or more excipients are the same or different to the excipients comprised in a reference medicinal product or reference biological product, wherein the reference medicinal product or reference biological product is urelumab.TABLE 5. Amino acid sequences for 4-1BB agonist antibodies related to urelumab.Identifier Sequence (One-Letter Amino Acid Symbols)SEQ ID NO:21 QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQS PEKGLEWIGE INHGGYVTYN 60 heavy chain for PSLESRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARDYG PGNYDWYFDL WGRGTLVTVS 120 urelumab SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS 180SGLYSLSSW TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS 240VFLFPPKPKD TLMISRTPEV TCVWDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300YRWSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT 360KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE 420GNVFSCSVMH EALHNHYTQK SLSLSLGK 448SEQ ID NO:22 EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA 60 light chain for RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPALTF CGGTKVEIKR TVAAPSVFIF 120 urelumab PPSDEQLKSG TASWCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST 180LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC 216SEQ ID NO:23 MKHLWFFLLL VAAPRWVLSQ VQLQQWGAGL LKPSETLSLT CAVYGGSFSG YYWSWIRQSP 60 variable heavy EKGLEWIGEI NHGGYVTYNP SLESRVTISV DTSKNQFSLK LSSVTAADTA VYYCARDYGP 120 chain forurelumabSEQ ID NO:24 MEAPAQLLFL LLLWLPDTTG EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP 60 variable light GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ 110 chain forurelumabSEQ ID NO:25 GYYWS 5 heavy chain CDR1for urelumabSEQ ID NO:26 EINHGGYVTY NPSLES 16 heavy chain CDR2for urelumabSEQ ID NO:27 DYGPGNYDWY FDL 13 heavy chain CDR3for urelumabSEQ ID NO:28 RASQSVSSYL A 11 light chain CDR1for urelumabSEQ ID NO:29 DASNRAT 7 light chain CDR2for urelumabSEQ ID NO:30 QQRSDWPPAL T 11 light chain CDR3for urelumab

[0801] In an embodiment, the 4- IBB agonist is selected from the group consisting of 1D8, 3Elor, 4B4 (BioLegend 309809), H4-1BB-M127 (BD Pharmingen 552532), BBK2 (Thermo Fisher MS621PABX), 145501 (Leinco Technologies B591), the antibody produced by ...

Claims

CLAIMSWe claim:

1. A method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3) antibody, peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist and a second TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to the patient.

2. The method of Claim 1, wherein the TNFRSF agonist is selected from the group consisting of a 4- IBB agonist, an OX40 agonist, a CD27 agonist, a GITR agonist, a HVEM agonist, a CD95 agonist, and combinations thereof.

3. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a 4- IBB agonist, and the 4- IBB agonist is selected from the group consisting of urelumab, utomilumab, EU- 101, a fusion protein, and fragments, derivatives, variants, biosimilars, and combinations thereof.

4. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is an OX40 agonist, or fragments, derivatives, variants, biosimilars, and combinations thereof.

5. The method of Claim 4, wherein the 4- IBB agonist fusion protein comprises (i) a firstsoluble 4- IBB binding domain, (ii) a first peptide linker, (iii) a second soluble 4- IBB binding domain, (iv) a second peptide linker, and (v) a third soluble 4- IBB binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

6. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a OX40 agonist, and the OX40 agonist is selected from the group consisting of tavolixizumab, GSK3174998, MEDI6469, MEDI6383, MOXR0916, PF-04518600, Creative Biolabs MOM-18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

7. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is an OX40 agonist, and the OX40 agonist is an OX40 agonist fusion protein.

8. The method of Claim 7, wherein the OX40 agonist fusion protein comprises (i) a first soluble OX40 binding domain, (ii) a first peptide linker, (iii) a second soluble OX40 binding domain, (iv) a second peptide linker, and (v) a third soluble OX40 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

9. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a CD27 agonist, and the CD27 agonist is varlilumab, or a fragment, derivative, variant, or biosimilar thereof.

10. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a CD27 agonist, and wherein the CD27 agonist is an CD27 agonist fusion protein.

11. The method of Claim 10, wherein the CD27 agonist fusion protein comprises (i) a firstsoluble CD27 binding domain, (ii) a first peptide linker, (iii) a second soluble CD27 binding domain, (iv) a second peptide linker, and (v) a third soluble CD27 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein thefusion protein is a dimeric structure according to structure I-A or structure I-B.

12. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a GITR agonist, and the GITR agonist is selected from the group consisting of TRX518, 6C8, 36E5, 3D6, 61G6, 6H6, 61F6, 1D8, 17F10, 35D8, 49A1, 9E5, 31H6, 2155, 698, 706, 827, 1649, 1718, 1D7, 33C9, 33F6, 34G4, 35B 10, 41E11, 41G5, 42A11, 44C1, 45A8, 46E11, 48H12, 48H7, 49D9, 49E2, 48 A9, 5H7, 7A10, 9H6, and fragments, derivatives, variants, biosimilars, and combinations thereof.

13. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is an GITR agonist, and the GITR agonist is a GITR agonist fusion protein.

14. The method of Claim 13, wherein the GITR agonist fusion protein comprises (i) a firstsoluble GITR binding domain, (ii) a first peptide linker, (iii) a second soluble GITR binding domain, (iv) a second peptide linker, and (v) a third soluble GITR binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

15. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a HVEM agonist.

16. The method of Claim 15, and the HVEM agonist is a HVEM agonist fusion protein.

17. The method of Claim 16, wherein the HVEM agonist fusion protein comprises (i) a first soluble HVEM binding domain, (ii) a first peptide linker, (iii) a second soluble HVEM binding domain, (iv) a second peptide linker, and (v) a third soluble HVEM binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

18. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a CD95 agonist.

19. The method of any one of Claims 1 to 2, wherein the TNFRSF agonist is a CD95 agonist, and the CD95 agonist is a CD95 agonist fusion protein.

20. The method of Claim 19, wherein the CD95 agonist is a fusion protein comprising (i) a first soluble CD95 binding domain, (ii) a first peptide linker, (iii) a second soluble CD95 binding domain, (iv) a second peptide linker, and (v) a third soluble CD95 binding domain, furthercomprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

21. The method of any one of Claims 1 to 20, further comprising the step of treating the patient with the TNFRSF agonist starting on the day after administration of the third population of TILs to the patient, wherein the TNFRSF agonist is administered intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

22. The method of any one of Claims 1 to 21, further comprising the step of treating the patient with the TNFRSF agonist prior to the step of resecting of a tumor from the patient, wherein the TNFRSF agonist is administered intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

23. The method of any one of Claims 1 to 22, wherein the TNFRSF agonist is selected from the group consisting of urelumab, utomilumab, EU-101, tavolixizumab, Creative Biolabs MOM- 18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

24. The method of any one of Claims 1 to 23, wherein the first cell culture medium comprises a second TNFRSF agonist.

25. The method of any one of Claims 1 to 23, wherein the TNFRSF agonist is a 4-1BB agonist, and the second TNFRSF agonist is an OX40 agonist.

26. The method of any one of Claims 1 to 25, wherein the TNFRSF agonist is added to the first cell culture medium during the initial expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

27. The method of any one of Claims 1 to 26, wherein the TNFRSF agonist is added to thesecond cell culture medium during the rapid expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

28. The method of any one of Claims 24 to 27, wherein the TNFRSF agonist is added at aconcentration sufficient to achieve a concentration in the cell culture medium of between 0.1 μg / mL and 100 μg / mL.

29. The method of Claim 28, wherein the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 μg / mL and 40 μg / mL.

30. The method of any one of Claims 1 to 30, wherein IL-2 is present at an initial concentration of about 10 to about 6000 R7 / mL in the first cell culture medium.

31. The method of Claim 31, wherein IL-2 is present at an initial concentration of about 3000 IU / mL in the first cell culture medium.

32. The method of Claim 31, wherein IL-2 is present at an initial concentration of about 800 to about 1100 IU / mL in the first cell culture medium.

33. The method of Claim 33, wherein IL-2 is present at an initial concentration of about 1000 IU / mL in the first cell culture medium.

34. The method of any one of Claims 1 to 30, wherein IL-2 is present at an initial concentration of about 10 to about 6000 R7 / mL in the second cell culture medium.

35. The method of Claim 35, wherein IL-2 is present at an initial concentration of about 3000 IU / mL in the second cell culture medium.

36. The method of Claim 35, wherein IL-2 is present at an initial concentration of about 800 to about 1100 IU / mL in the second cell culture medium.

37. The method of Claim 35, wherein IL-2 is present at an initial concentration of about 1000 IU / mL in the second cell culture medium.

38. The method of any one of Claims 1 to 37, wherein IL-15 is present in the first cell culture medium.

39. The method of Claim 38, wherein IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

40. The method of any one of Claims 1 to 39, wherein IL-15 is present in the second cell culture medium.

41. The method of Claim 40, wherein IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

42. The method of any one of Claims 1 to 41, wherein IL-21 is present in the first cell culturemedium.

43. The method of Claim 42, wherein IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

44. The method of any one of Claims 1 to 43, wherein IL-21 is present in the second cell culture medium.

45. The method of Claim 44, wherein IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

46. The method of any one of Claims 1 to 45, wherein OKT-3 antibody is present at an initial concentration of about 10 ng / mL to about 60 ng / mL in the second cell culture medium.

47. The method of Claim 46, wherein OKT-3 antibody is present at an initial concentration of about 30 ng / mL in the second cell culture medium.

48. The method of any one of Claims 1 to 47, wherein the initial expansion is performed using a gas permeable container.

49. The method of any one of Claims 1 to 48, wherein the rapid expansion is performed using a gas permeable container.

50. The method of any one of Claims 1 to 49, further comprising the step of treating the patient with a non-myeloablative lymphodepletion regimen prior to administering the third population of TILs to the patient.

51. The method of Claim 50, wherein the non-myeloablative lymphodepletion regimencomprises the steps of administration of cyclophosphamide at a dose of 60 mg / m2 / day for two days followed by administration of fludarabine at a dose of 25 mg / m2 / day for five days.

52. The method of any one of Claims 1 to 51, further comprising the step of treating the patient with a decrescendo IL-2 regimen starting on the day after administration of the third population of TILs to the patient, wherein the decrescendo IL-2 regimen comprises aldesleukin administered intravenously at a dose of 18,000,000 IU / m2on day 1, 9,000,000 IU / m2on day 2, and 4,500,000 IU / m2on days 3 and 4.

53. The method of any one of Claims 1 to 51, further comprising the step of treating the patient with pegylated IL-2 after administration of the third population of TILs to the patient at adose of 0.10 mg / day to 50 mg / day.

54. The method of any one of Claims 1 to 51, further comprising the step of treating the patient with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs to the patient.

55. The method of Claim 54, wherein the high-dose IL-2 regimen comprises 600,000 or 720,000 IU / kg of aldesleukin, or a biosimilar or variant thereof, administered as a 15-minute bolus intravenous infusion every eight hours until tolerance.

56. The method of any one of Claims 1 to 55, wherein the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, renal cell carcinoma, acute myeloid leukemia, colorectal cancer, cholangiocarcinoma, and sarcoma.

57. The method of any one of Claims 1 to 56, wherein the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), triple negative breast cancer, double- refractory melanoma, and uveal (ocular) melanoma.

58. The method of any one of Claims 1 to 57, further comprising the step of treating the patient with a PD-1 inhibitor or PD-Ll inhibitor prior to resecting the tumor from the patient.

59. The method of Claim 58, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

60. The method of any one of Claims 1 to 59, further comprising the step of treating the patient with a PD-1 inhibitor or PD-Ll inhibitor after resecting the tumor from the patient.

61. The method of Claim 60, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

62. The method of any one of Claims 1 to 61, further comprising the step of treating the patient with a PD-1 inhibitor or PD-Ll inhibitor after administering the third population of TILs to the patient.

63. The method of Claim 62, wherein the PD-1 inhibitor or PD-Ll inhibitor is selected from thegroup consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

64. The method of any one of Claims 1 to 63, wherein the first cell culture medium furthercomprises IL-4, IL-7, or a combination thereof.

65. The method of any one of Claims 1 to 64, wherein the second cell culture medium further comprises IL-4, IL-7, or a combination thereof.

66. The method of any one of Claims 1 to 65, wherein the initial expansion is performed over a period of 11 days or less.

67. The method of any one of Claims 1 to 65, wherein the rapid expansion is performed over a period of 11 days or less.

68. A process for the preparation of a population of tumor infiltrating lymphocytes (TILs)comprising the steps of:(b) obtaining a first population of TILs;(c) performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2 and a tumor necrosis factor receptor superfamily (TNFRSF) agonist, and wherein the initial expansion is performed over a period of 21 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days from the start of the rapid expansion; wherein the second cell culture medium comprises IL-2, OKT-3 (anti- CD3 antibody), peripheral blood mononuclear cells (PBMCs), and optionally the TNFRSF agonist, and wherein the rapid expansion is performed over a period of 14 days or less; and(e) harvesting the third population of TILs.

69. The process according to claim 68 wherein the first population of TILs is obtained from a tumor which tumor has been resected from a patient.

70. The process according to any one of claims 68 to 69, wherein the TNFRSF agonist is selected from the group consisting of a 4-lBB agonist, an OX40 agonist, a CD27 agonist, a GITR agonist, a HVEM agonist, a CD95 agonist, and combinations thereof.

71. The process according to any one of claims 68 to 70, wherein the TNFRSF agonist is a 4- 1BB agonist.

72. The process according to any one of claims 68 to 71, the TNFRSF agonist is a 4- IBBagonist, and the 4-lBB agonist is selected from the group consisting of urelumab, utomilumab, EU-101, and fragments, derivatives, variants, biosimilars, and combinations thereof.

73. The process according to any one of claims 68 to 72, wherein the TNFRSF agonist is a 4- 1BB agonist, and the 4- IBB agonist is a 4- IBB agonist fusion protein.

74. The process according to any one of claims 68 to 73, wherein the TNFRSF agonist is a 4- 1BB agonist fusion protein, and the 4-lBB agonist fusion protein comprises (i) a first soluble 4-lBB binding domain, (ii) a first peptide linker, (iii) a second soluble 4-lBB binding domain, (iv) a second peptide linker, and (v) a third soluble 4- IBB binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

75. The process according to any one of claims 68 to 74, wherein the TNFRSF agonist is a OX40 agonist.

76. The process according to any one of claims 68 to 75, wherein the TNFRSF agonist is a OX40 agonist, and the OX40 agonist is selected from the group consisting of tavolixizumab, GSK3174998, MEDI6469, MEDI6383, MOXR0916, PF-04518600, Creative Biolabs MOM- 18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

77. The process according to any one of claims 68 to 76, wherein the TNFRSF agonist is an OX40 agonist, and the OX40 agonist is an OX40 agonist fusion protein.

78. The process according to any one of claims 68 to 77, wherein the TNFRSF agonist is an OX40 agonist fusion protein, and the OX40 agonist fusion protein comprises (i) a first soluble OX40 binding domain, (ii) a first peptide linker, (iii) a second soluble OX40 bindingdomain, (iv) a second peptide linker, and (v) a third soluble OX40 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

79. The process according to any one of claims 68 to 78, wherein the TNFRSF agonist is a CD27 agonist.

80. The process according to any one of claims 68 to 79, wherein the TNFRSF agonist is a CD27 agonist, and the CD27 agonist is varlilumab, or a fragment, derivative, variant, or biosimilar thereof.

81. The process according to any one of claims 68 to 80, wherein the TNFRSF agonist is a CD27 agonist, and wherein the CD27 agonist is an CD27 agonist fusion protein.

82. The process according to any one of claims 68 to 81, wherein the TNFRSF agonist is a CD27 agonist, and the CD27 agonist fusion protein comprises (i) a first soluble CD27 binding domain, (ii) a first peptide linker, (iii) a second soluble CD27 binding domain, (iv) a second peptide linker, and (v) a third soluble CD27 binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

83. The process according to any one of claims 68 to 82, wherein the TNFRSF agonist is a GITR agonist.

84. The process according to any one of claims 68 to 83, wherein the TNFRSF agonist is a GITR agonist, and the GITR agonist is selected from the group consisting of TRX518, 6C8, 36E5, 3D6, 61G6, 6H6, 61F6, 1D8, 17F10, 35D8, 49A1, 9E5, 31H6, 2155, 698, 706, 827, 1649, 1718, 1D7, 33C9, 33F6, 34G4, 35B 10, 41E11, 41G5, 42A11, 44C1, 45A8, 46E11, 48H12, 48H7, 49D9, 49E2, 48 A9, 5H7, 7A10, 9H6, and fragments, derivatives, variants, biosimilars, and combinations thereof.

85. The process according to any one of claims 68 to 84, wherein the TNFRSF agonist is anGITR agonist and the GITR agonist is a GITR agonist fusion protein.

86. The process according to any one of claims 68 to 85, wherein the TNFRSF agonist is a GITR agonist fusion protein, and the GITR agonist fusion protein comprises (i) a first soluble GITR binding domain, (ii) a first peptide linker, (iii) a second soluble GITR binding domain, (iv) a second peptide linker, and (v) a third soluble GITR binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I- A or structure I-B.

87. The process according to any one of claims 68 to 86, wherein the TNFRSF agonist is aHVEM agonist.

88. The process according to any one of claims 68 to 87, wherein the TNFRSF agonist is an HVEM agonist, and the HVEM agonist is a HVEM agonist fusion protein.

89. The process according to any one of claims 68 to 88, wherein the TNFRSF agonist is aHVEM agonist fusion protein, and wherein the HVEM agonist fusion protein comprises (i) a first soluble HVEM binding domain, (ii) a first peptide linker, (iii) a second soluble HVEM binding domain, (iv) a second peptide linker, and (v) a third soluble HVEM binding domain, further comprising an additional domain at the N-terminal and / or C-terminal end, and wherein the additional domain comprises a Fc fragment domain and hinge domain, and wherein the fusion protein is a dimeric structure according to structure I-A or structure I-B.

90. The process according to any one of claims 68 to 89, wherein the TNFRSF agonist isselected from the group consisting of urelumab, utomilumab, EU-101, tavolixizumab, Creative Biolabs MOM-18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

91. The process according to any one of claims 68 to 90, wherein the first cell culture medium comprises a second TNFRSF agonist.

92. The process according to any one of claims 68 to 91, wherein the TNFRSF agonist is added to the first cell culture medium during the initial expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

93. The process according to any one of claims 68 to 92, wherein the TNFRSF agonist is added to the second cell culture medium during the rapid expansion at an interval selected from the group consisting of every day, every two days, every three days, every four days, every five days, every six days, every seven days, and every two weeks.

94. The process according to any one of claims 68 to 93, wherein the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 0.1 μg / mL and 100 μg / mL.

95. The process according to any one of claims 68 to 94, wherein the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 μg / mL and 40 μg / mL.

96. The process according to any one of claims 68 to 95, wherein IL-2 is present at an initial concentration of about 10 to about 6000 IU / mL in the first cell culture medium.

97. The process according to any one of claims 68 to 96, wherein IL-2 is present at an initial concentration of about 3000 IU / mL in the first cell culture medium.

98. The process according to any one of claims 68 to 97, wherein IL-2 is present at an initial concentration of about 800 to about 1100 R7 / mL in the first cell culture medium.

99. The process according to any one of claims 68 to 98, wherein IL-2 is present at an initial concentration of about 1000 IU / mL in the first cell culture medium.

100. The process according to any one of claims 68 to 99, wherein IL-2 is present at an initial concentration of about 10 to about 6000 IU / mL in the second cell culture medium.

101. The process according to any one of claims 68 to 100, wherein IL-2 is present at an initial concentration of about 3000 IU / mL in the second cell culture medium.

102. The process according to any one of claims 68 to 101, wherein IL-2 is present at an initial concentration of about 800 to about 1100 IU / mL in the second cell culture medium.

103. The process according to any one of claims 68 to 102, wherein IL-2 is present at an initial concentration of about 1000 IU / mL in the second cell culture medium.

104. The process according to any one of claims 68 to 103, wherein IL-15 is present in the first cell culture medium.

105. The process according to any one of claims 68 to 104, wherein IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

106. The process according to any one of claims 68 to 105, wherein IL-15 is present in thesecond cell culture medium.

107. The process according to any one of claims 68 to 106, wherein IL-15 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

108. The process according to any one of claims 68 to 107, wherein IL-21 is present in the first cell culture medium.

109. The process according to any one of claims 68 to 108, wherein IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the first cell culture medium.

110. The process according to any one of claims 68 to 109, wherein IL-21 is present in thesecond cell culture medium.

111. The process according to any one of claims 68 to 110, wherein IL-21 is present at an initial concentration of about 5 ng / mL to about 20 ng / mL in the second cell culture medium.

112. The process according to any one of claims 68 to 111, wherein OKT-3 antibody is present at an initial concentration of about 10 ng / mL to about 60 ng / mL in the second cell culture medium.

113. The process according to any one of claims 68 to 112, wherein OKT-3 antibody is present at an initial concentration of about 30 ng / mL in the second cell culture medium.

114. The process according to any one of claims 68 to 113, wherein the initial expansion is performed using a gas permeable container.

115. The process according to any one of claims 68 to 114, wherein the rapid expansion isperformed using a gas permeable container.

116. A population of tumor infiltrating lymphocytes (TILs) obtainable from a process according to any one of claims 68 to 115.

117. A pharmaceutical composition comprising a population of tumor infiltrating lymphocytes (TILs) for use in treating a cancer wherein the population of tumor infiltrating lymphocytes (TILs) is obtainable by a process according to any one of claims 68 to 115, whereinoptionally the pharmaceutical composition comprises the third population of TILs.

118. The pharmaceutical composition for use in the treatment of a cancer according to claim 117, wherein the pharmaceutical composition is for use in combination with a T FRSF agonist.

119. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a TNFRSF agonist wherein the TNFRSF agonist is for administration on the day after administration of the third population of TILs to the patient, and wherein the TNFRSF agonist is administered intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

120. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a TNFRSF agonist wherein the TNFRSF agonist is for administration prior to the step of resecting of a tumor from the patient, and wherein the TNFRSF agonist is for administration intravenously at a dose of between 0.1 mg / kg and 50 mg / kg every four weeks for up to eight cycles.

121. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 for use in combination with a non-myeloablative lymphodepletion regimen.

122. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a myeloablative lymphodepletion regimen prior to administering the third population of TILs to the patient.

123. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a myeloablative lymphodepletion regimen wherein the non-myeloablative lymphodepletion regimen is for administration prior to administering the third population of TILs to the patient, and wherein the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg / m2 / day for two days followed by administration of fludarabine at a dose of 25 mg / m2 / day for five days.

124. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a decrescendo IL-2 regimen.

125. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a decrescendo IL-2 regimen starting on the day after administration of the third population of TILs to the patient, wherein the decrescendo IL-2 regimen comprises aldesleukin administered intravenously at a dose of 18,000,000 IU / m2on day 1, 9,000,000 IU / m2on day 2, and 4,500,000 IU / m2on days 3 and 4.

126. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with pegylated IL-2.

127. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with pegylated IL-2 administered after administration of the third population of TILs to the patient at a dose of 0.10 mg / day to 50 mg / day.

128. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a high-dose IL-2 regimen.

129. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs to the patient.

130. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a high-dose IL-2 regimen starting on the day after administration of the third population of TILs to the patient, wherein the high-dose IL-2 regimen comprises 600,000 or 720,000 IU / kg of aldesleukin, or a biosimilar or variant thereof, administered as a 15-minute bolus intravenous infusion every eight hours until tolerance.

131. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor.

132. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

133. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor, wherein the PD-1 inhibitor or PD-L1 inhibitor is administered prior to resection of the tumor from the patient.

134. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor prior to resection of the tumor from the patient, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

135. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor after resection a tumor from the patient.

136. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor after resection of the tumor from the patient, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

137. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor orPD-L1 inhibitor which is for administration after administering the third population of TILs to the patient.

138. The pharmaceutical composition for use in the treatment of a cancer according to claim 117 wherein the pharmaceutical composition is for use in combination with a PD-1 inhibitor or PD-L1 inhibitor which is for administration after administering the third population of TILs to the patient, wherein the PD-1 inhibitor or PD-L1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, biosimilars, and combinations thereof.

139. The pharmaceutical composition for use in the treatment of a cancer according to any one of claims 117 to 138 wherein the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, renal cell carcinoma, acute myeloid leukemia, colorectal cancer,cholangiocarcinoma, and sarcoma.

140. The pharmaceutical composition for use in the treatment of a cancer according to any one of claims 117 to 138, wherein the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), triple negative breast cancer, double-refractory melanoma, and uveal (ocular) melanoma.

141. A method of treating a cancer with a population of tumor infiltrating lymphocytes (TILs) comprising the steps of:(a) resecting a tumor from a patient;(b) obtaining a first population of TILs from the tumor;(c) performing an initial expansion of the first population of TILs in a first cell culturemedium to obtain a second population of TILs, wherein the second population of TILs is at least 5-fold greater in number than the first population of TILs, wherein the first cell culture medium comprises IL-2, and wherein the initial expansion is performed over a period of 11 days or less;(d) performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7 days fromthe start of the rapid expansion; wherein the second cell culture medium comprises IL- 2, OKT-3 (anti-CD3) antibody, peripheral blood mononuclear cells (PBMCs), and a TNFRSF agonist, and wherein the rapid expansion is performed over a period of 11 days or less;(e) harvesting the third population of TILs; and(f) administering a therapeutically effective portion of the third population of TILs to the patient.

142. The method of Claim 141, wherein the TNFRSF agonist is selected from the groupconsisting of a 4-1BB agonist, an OX40 agonist, and a combination thereof.

143. The method of Claim 142, wherein the TNFRSF agonist is a 4-1BB agonist, and the 4-1BB agonist is selected from the group consisting of urelumab, utomilumab, EU-101, a fusion protein, and fragments, derivatives, variants, biosimilars, and combinations thereof.

144. The method of Claim 142, wherein the TNFRSF agonist is a OX40 agonist, and the OX40 agonist is selected from the group consisting of tavolixizumab, GSK3174998, MEDI6469, MEDI6383, MOXR0916, PF-04518600, Creative Biolabs MOM- 18455, and fragments, derivatives, variants, biosimilars, and combinations thereof.

145. The method of any one of Claims 141 to 144, wherein the TNFRSF agonist is present at the start of step (d) at a concentration between 1 μg / mL and 30 μg / mL.

146. The method of Claim 145, wherein the TNFRSF agonist is present at the start of step (d) at a concentration between 5 μg / mL and 20 μg / mL.

147. The method of Claim 146, wherein the TNFRSF agonist is present at the start of step (d) at a concentration of about 10 μg / mL.

148. The method of any one of Claims 141 to 144, wherein the TNFRSF agonist is maintained throughout step (d) at a concentration between 1 μg / mL and 30 μg / mL.

149. The method of Claim 145, wherein the TNFRSF agonist is maintained throughout step (d) at a concentration between 5 μg / mL and 20 μg / mL.

150. The method of Claim 146, wherein the TNFRSF agonist is maintained throughout step (d) at a concentration of about 10 μg / mL.

151. The method of any one of Claims 141 to 150, wherein the third population of TILs exhibits an increased ratio of CD8+TILs to CD4+TILs in comparison to the reference ratio of CD8+TILs to CD4+TILs in the second population of TILs.

152. The method of Claim 151, wherein the increased ratio is at least 5% greater than thereference ratio.

153. The method of Claim 152, wherein the increased ratio is at least 10% greater than thereference ratio.

154. The method of Claim 153, wherein the increased ratio is at least 20% greater than thereference ratio.

155. The method of Claim 154, wherein the increased ratio is at least 35% greater than thereference ratio.

156. The method of Claim 155, wherein the increased ratio is at least 50% greater than thereference ratio.

157. The method of any one of Claims 141 to 156, wherein the cancer is selected from the group consisting of melanoma, uveal (ocular) melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer (head and neck squamous cell cancer), renal cell carcinoma, colorectal cancer, pancreatic cancer, glioblastoma, cholangiocarcinoma, and sarcoma.

158. The method of any one of Claims 141 to 156, wherein the cancer is selected from the group consisting of cutaneous melanoma, uveal (ocular) melanoma, platinum -resistant ovarian cancer, pancreatic ductal adenocarcinoma, osteosarcoma, triple-negative breast cancer, and non-small-cell lung cancer.

Images